Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients

Oslo, Norway, 4 December 2016 Nordic Nanovector ASA (OSE: NANO) presented today the updated results from its ongoing Lymrit 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed non-Hodgkin lymphoma (NHL) at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA). The updated data confirm Betalutin®’s promising efficacy and favourable safety profile as a single agent in 38 relapsed NHL patients, having failed multiple prior regimens and being eligible for assessments. The results, based on the data cut-off date of 31 October 2016, were presented by the study’s Principal Investigator Dr. Arne Kolstad from the Department of Oncology at the Oslo University Hospital, Radiumhospitalet. Key conclusions: • In the 35 patients evaluable for efficacy, the Overall Response Rate (ORR) was 63%, with 29% Complete Responses (CR) • The 21 evaluable patients in the study who received Betalutin® at the dose of 15 MBq/kg with 40 mg/m2 lilotomab pre-dosing had an ORR of 62% and a CR of 38%; of these, the 16 patients enrolled in the Phase 2 expansion of Arm 1, had an ORR of 69% and a CR of 38% • Durable responses have been observed with a median duration of response of 20.7 months for all patients in Arm 1 • Betalutin® is well tolerated, with a predictable and manageable safety profile: most adverse events are haematological in nature, and all have been transient and reversible • No dose-limiting toxicity (DLT) was reported in Arm 4 (15 MBq/kg Betalutin® plus 100 mg/m2 lilotomab pre-dosing) and this regimen demonstrated lower bone marrow toxicity than Arm 1, 2 and 3. Arm 4 is now enrolling patients to evaluate the higher dosing regimen of 20 MBq/kg Betalutin® plus 100 mg/m2 lilotomab. The Lymrit 37-01 study is a Phase 1/2 open label, dose escalation study investigating the optimal lilotomab pre-dosing and Betalutin® regimen in patients with relapsed NHL. Data from 38 patients are presented. Dr. Arne Kolstad, MD commented: “The results we are presenting today are very encouraging and continue to highlight the potential of Betalutin® to provide a new treatment option for NHL patients. These patients, particularly those who fail standard CD20-targeted immunotherapy and/or are too frail to receive chemotherapy, are desperately in need of alternative therapies that work through different and complementary mechanisms and are well tolerated. Betalutin® is showing exciting promise in an increasing number of NHL patients and we look forward to the results from future studies that will hopefully confirm its attractive profile.” Dr. Lisa Rojkjaer, MD Nordic Nanovector’s Chief Medical Officer, commented: “These new data confirm the promising results for Betalutin®, including durable responses in a number of patients, which were presented earlier this year at the AACR meeting, and continue to demonstrate an encouraging clinical profile as a single agent for treating patients with relapsed NHL. The results also support escalating to a higher dosing regimen in the final stages of this Phase 1/2 study that will allow us to decide an optimal dosing regimen for the pivotal Phase 2 study, PARADIGME, expected in Q1 2017.” The poster (abstract 1780) is available at: http://www.nordicnanovector.com/product-info/scientific-posters. Conference call details A conference call will take place on Monday 5 December at 11 am CET. Please make sure to dial in 5-10 minutes prior to scheduled conference call start time using the number and confirmation code below: Local – Norway +47 2350 0296Local – UK +44 (0)330 336 9411Local – USA and International +1 719 457 1036 Conference ID: 2949173 The conference call presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/2016 from 10 am CET on Monday 5 December 2016. For further information, please contact: For Nordic NanovectorIR enquiries:Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients

Oslo, Norway, 5 December 2016 Nordic Nanovector ASA (OSE: NANO) presented yesterday the updated results from its ongoing Lymrit 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed non-Hodgkin lymphoma (NHL) at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA). This press release was previously issued on Sunday 4 December at 2:30am CET. A conference call will be held today at 11 am CET. Please see conference call details below. The updated data confirm Betalutin®’s promising efficacy and favourable safety profile as a single agent in 38 relapsed NHL patients, having failed multiple prior regimens and being eligible for assessments. The results, based on the data cut-off date of 31 October 2016, were presented by the study’s Principal Investigator Dr. Arne Kolstad from the Department of Oncology at the Oslo University Hospital, Radiumhospitalet. Key conclusions: • In the 35 patients evaluable for efficacy, the Overall Response Rate (ORR) was 63%, with 29% Complete Responses (CR) • The 21 evaluable patients in the study who received Betalutin® at the dose of 15 MBq/kg with 40 mg/m2 lilotomab pre-dosing had an ORR of 62% and a CR of 38%; of these, the 16 patients enrolled in the Phase 2 expansion of Arm 1, had an ORR of 69% and a CR of 38% • Durable responses have been observed with a median duration of response of 20.7 months for all patients in Arm 1 • Betalutin® is well tolerated, with a predictable and manageable safety profile: most adverse events are haematological in nature, and all have been transient and reversible • No dose-limiting toxicity (DLT) was reported in Arm 4 (15 MBq/kg Betalutin® plus 100 mg/m2 lilotomab pre-dosing) and this regimen demonstrated lower bone marrow toxicity than Arm 1, 2 and 3. Arm 4 is now enrolling patients to evaluate the higher dosing regimen of 20 MBq/kg Betalutin® plus 100 mg/m2 lilotomab. The Lymrit 37-01 study is a Phase 1/2 open label, dose escalation study investigating the optimal lilotomab pre-dosing and Betalutin® regimen in patients with relapsed NHL. Data from 38 patients are presented. Dr. Arne Kolstad, MD commented: “The results we are presenting today are very encouraging and continue to highlight the potential of Betalutin® to provide a new treatment option for NHL patients. These patients, particularly those who fail standard CD20-targeted immunotherapy and/or are too frail to receive chemotherapy, are desperately in need of alternative therapies that work through different and complementary mechanisms and are well tolerated. Betalutin® is showing exciting promise in an increasing number of NHL patients and we look forward to the results from future studies that will hopefully confirm its attractive profile.” Dr. Lisa Rojkjaer, MD Nordic Nanovector’s Chief Medical Officer, commented: “These new data confirm the promising results for Betalutin®, including durable responses in a number of patients, which were presented earlier this year at the AACR meeting, and continue to demonstrate an encouraging clinical profile as a single agent for treating patients with relapsed NHL. The results also support escalating to a higher dosing regimen in the final stages of this Phase 1/2 study that will allow us to decide an optimal dosing regimen for the pivotal Phase 2 study, PARADIGME, expected in Q1 2017.” The poster (abstract 1780) was presented on Saturday, 3 December 2016 between 5:30PM–7:30PM Pacific Standard Time (Oslo: Sunday 4 December, 2:30AM–4:30AM CET) and is available at: http://www.nordicnanovector.com/product-info/scientific-posters. Conference call details A conference call will take place today, Monday 5 December at 11 am CET. Please make sure to dial in 5-10 minutes prior to scheduled conference call start time using the number and confirmation code below: Local – Norway +47 2350 0296Local – UK +44 (0)330 336 9411Local – USA and International +1 719 457 1036 Conference ID: 2949173 The conference call presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/2016 from 10 am CET today, Monday 5 December 2016. For further information, please contact: For Nordic NanovectorIR enquiries:Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Alimak Group acquires Avanti Wind Systems and intends to propose a rights issue of up to 800 MSEK

Avanti offers vertical access solutions to the wind industry that are permanently installed, have a long lifecycle and are based on high safety requirements. Avanti was established in 1885 and has more than 30,000 service lifts installed globally. In 2016, Avanti´s net sales is expected to be 98 MEUR and it operates globally with six production facilities in Denmark, Spain, China, US and Brazil. “The demand for service lifts for wind turbine towers is expected to grow the coming years due to increased heights of the towers and increased safety requirements. The acquisition expands and diversifies our offering of vertical access solutions for industrial customers globally, enables cross selling opportunities and adds an opportunity to expand after sales well in line with Alimak´s strategy and business model”, says Tormod Gunleiksrud, CEO of Alimak Group.  “Becoming part of Alimak Group enables Avanti to continue its development of best in class safety products and solutions to the benefit of our customers within the wind industry. I see this acquisition as the perfect strategic fit for Avanti, and we look forward to becoming part of the global leader in vertical access systems” says Erik Laursen, CEO of Avanti Group.  Through the acquisition, Alimak Group takes another step forward in the global vertical access industry and the annual group net sales will increase from approximately 3,200 MSEK to 4,200 MSEK, while the number of employees will rise from 1,900 to 2,300. The globally installed base will increase from around 36,000 to 66,000 units. The acquisition is subject to customary regulatory approvals and is expected to close in the first quarter of 2017. Synergies will primarily be found in the supply chain, through cross-selling and in expansion of the aftersales offering. The acquisition is expected to be EPS accretive and contribute positively to cash flow. Integration costs are estimated to approximately 43 MSEK. The acquisition will be financed through a bridge loan arranged by Alimak Group´s existing banks. Upon completion of the acquisition, Alimak Group will have a capital structure with an expected leverage (net debt/EBITDA) of around 3.7x, which exceeds the targeted leverage of 2.0x. In accordance with Alimak Group’s financial targets, Alimak Group’s capital structure shall enable a high degree of financial flexibility and allow for strategic initiatives. Therefore the Board of Alimak Group will call for an Extraordinary General Meeting of shareholders to be held in January 2017 in order to obtain an authorisation for the Board to resolve on a rights issue of up to 800 MSEK with preferential rights for existing shareholders. The rights issue will be launched sometime after the year-end report has been published and is expected to be completed during the beginning of the second quarter of 2017. Due to the recent acquisitions of Facade Access Group and Avanti during the fourth quarter, Alimak Group will postpone the release of the Year End report 2016 until February 23 2017 (initially scheduled for release on February 17). In the afternoon on February 23, Alimak Group will host an investor update which will include a presentation of revised financial targets for the Group.  A notice to the EGM will be published separately and will be made available at www.alimakgroup.com. A detailed time plan and conditions for the rights issue will be announced at a later stage. Alimak Group´s main shareholders, Triton, Lannebo Fonder, Swedbank Robur and York Capital Management, who together control close to 60% of the share capital and the votes, have indicated their intention to at the EGM vote in favor of authorizing the Board to resolve on the rights issue and declared their intent to subscribe for their respective shares in the rights issue.   Alimak Group was advised by Kirkland & Ellis in connection with the acquisition of Avanti. Telephone conference and audiocast: Alimak Group´s CEO, Tormod Gunleiksrud and CFO, Stefan Rinaldo, will present the acquisition at a telephone conference and audiocast on Monday December 5, 2016 at 11.00 CET. SE: +46 856642699  UK: +44 (0)2030089807 The presentation can also be followed via webcast:  https://wonderland.videosync.fi/alimak-group-press-conference  For further information:Sofia Wretman, Head of Communications & IR, Phone: +46 8 402 14 40 The information in this release is such that Alimak Group is obliged to make public pursuant to the EU Market Abuse Regulation and, as applicable, the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at December 5, 2016, 07.30 CET. Alimak GroupAlimak Group is a world-leading supplier of elevators, platforms and after-market service for the industrial and construction sectors. The Group has manufacturing operations in Sweden and China and a sales and servicing network in more than 90 countries supplying and maintaining vertical access solutions. At present, more than 22,000 elevators and platforms are installed globally. Alimak was established in Skellefteå in 1948 and has 1,200 employees around the world. The Group is listed on Nasdaq Stockholm. www.alimakgroup.com  Avanti Group Avanti is a world leading supplier of service lifts, safety ladder systems, safety equipment, tower internals and after-market service for wind turbine towers. The group has manufacturing facilities in Denmark, Spain, China, US and Brazil and sales offices in 9 countries supplying and servicing customers in all major markets for wind power. As of today Avanti has more than 30,000 service lifts installed globally. Avanti was established in Copenhagen in 1885 and today Avanti has more than 400 employees throughout the world.  www.avanti-online.com

NetEnt enters Mexico with Codere

NetEnt continues to expand globally on regulated markets with its innovative digital gaming solutions and has now signed an agreement with Spanish gaming operator Codere to enter the online market in Mexico. Codere is an existing customer of NetEnt and has a significant presence on the traditional land-based casino markets in Spain, Italy and Latin America. Codere is one of the largest casino operators in Mexico and has an operator license for both land-based and online casino operations. NetEnt will be able to provide its portfolio offerings to Codere through Codere’s existing operator license. ”I am really excited to enter the regulated online casino market in Mexico together with Codere. This is our first market entry in Latin America and marks another milestone as we follow our long-term strategy to enter and grow in new regulated markets. I’m convinced that we can support Codere’s online casino growth and that players in Mexico will enjoy our world-class thrilling games”, says Björn Krantz, Managing Director of NetEnt Americas LLC. For additional information please contact:Björn Krantz, Managing Director of NetEnt Americas LLCPhone +1 646 647 5670bjorn.krantz@netent.com Roland Glasfors, Investor Relations, NetEnt AB (publ)Phone +46 760 024 863roland.glasfors@netent.com This information is information that NetEnt AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on December 5, 2016. About NetEntNetEnt AB (publ) is a leading digital entertainment company, providing premium gaming solutions to the world’s most successful online casino operators. Since its inception in 1996, NetEnt has been a true pioneer in driving the market with thrilling games powered by a cutting-edge platform. NetEnt is committed to helping customers stay ahead of the competition, is listed on NASDAQ Stockholm (NET–B) and employs 900 people in Stockholm, Malta, Kiev, Krakow, Gothenburg, Gibraltar and New Jersey. www.netent.com

Senzime signs license agreement with Fukuda Denshi

Fukuda Denshi is one of the global market leaders in the field of patient monitoring. The company was founded in 1939 and reported global revenues in excess of JPY 100 billion in 2015. Pursuant to the Agreement, Fukuda licenses the TetraGraph technology to exclusively commercialize a handheld monitoring system under its own brand on the Japanese market. Furthermore, Fukuda is granted rights to develop, at its own expense, an integrated modular system based on the TetraGraph technology. This latter solution is to be offered as an accessory to Fukuda’s installed base of patient monitors in Japan. "This is a major milestone for Senzime and the first major commercialization step in our journey to become a leader in patient monitoring. Fukuda is one of the world's leading companies in this field and the joint long-term commitment proves the competitiveness of our product offering. It’s certainly a breakthrough for Senzime", says Lena Söderström, CEO of Senzime AB. The Senzime TetraGraph is a monitoring system developed to meet today's high standards of usability and reliability. Objective and preventive monitoring of patients undergoing anesthesia with neuromuscular blocking agents was proven to reduce the risk of complications by more than 50%, resulting in great benefits for patients and healthcare providers. The license agreement includes fixed milestone payments as well as fixed license fees based on actual sales. The license fees are not disclosed. The fist products are expected to be launched in Japan in late 2017, and for the fiscal year of 2017, Senzime expects fixed license fees of SEK 4 million. The license fees are paid to Senzime on a quarterly basis. Fukuda will source components directly from designated suppliers; hence, Senzime will not carry any inventory for Fukuda, have any cost of goods sold related to the license fees, or have any other working capital needs in relation to the agreement. In Japan, approximately 2.7 million patients undergo surgery and general anesthesia in approximately 13,500 operating rooms1. This represents approximately 2% of the global market2. The agreement with Fukuda spans 10 years and is expected by Senzime’s management and board to generate more than 100 MSEK in license revenues in the form of fixed and variable royalty payments based on sales of products with Senzime’s technology. The forecast is substantiated by Senzimes assumptions of increased volumes and the license fees agreed upon during the contract period, however, sales quota are not guaranteed by Fukuda. For further information, please contact: Lena Söderström, CEO of Senzime AB Tel: +46-708-16 39 12, email: lena.soderstrom@senzime.com 1. Yano Research Institute Ltd (report 2014), and Fukuda Denshi. 2. There are 405,000 operating rooms worldwide (Lancet 2010: Global operating theatre distribution and pulse oximetry supply: an estimation from reported data Funk LM, et al.) and 234.2 million patients (Lancet 2008: An estimation of the global volume of surgery: a modelling strategy based on available data. Weiser TG (https://www.ncbi.nlm.nih.gov/pubmed/?term=Weiser%20TG%5BAuthor%5D&cauthor=true&cauthor_uid=18582931) et al.) TO THE EDITORS About Senzime Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com About Fukuda Denshi FUKUDA DENSHI, which succeeded in 1939 in developing the first electrocardiograph (ECG) ever produced in Japan, has continued enhancing its know-how as a pioneer of the electrocardiograph in this country while building a firm foundation in the medical equipment industry and continuing to grow along with the daily-evolving health and medicine fields. The FUKUDA DENSHI Group is a manufacturer specialized in medical instruments, which provides products and services utilizing our accumulated wide-ranging resources in the medical field to offer total support "from medical examination to medical treatment and first aid, and even home medical care." FUKUDA DENSHI is publicly traded on JASDAQ. http://www.fukuda.co.jp

New weapon against the shadow economy - tax authorities to receive VAT information in real time

Tieto and the Federation of Finnish Financial Services have presented an initiative on digitalized value-added tax (VAT) reporting. The new standard would allow companies to report VAT information faster and facilitate real-time reporting. Adopting a uniform standard could help to increase European tax revenues by up to EUR 160 billion a year. The new ISO 20022 standard devised and developed by Tieto and the Federation of Finnish Financial Services will help to enable real-time value added tax (VAT) reporting. The standard allows the necessary information in each invoice to be reported to the tax authorities in digital form. Adopting the new standard across Europe could potentially increase tax revenues by up to EUR 160 billion through the collection of currently unreported VAT. - Digitalization is the best weapon for combatting the shadow economy. The newly published standard for easy VAT reporting will help to advance the transition towards electronic invoicing in Europe. It will also lighten the burden of reporting carried by the companies by means of automatization and real-time reporting. We are proud to have been able to contribute to the fight against the shadow economy by offering efficient new digital tools for companies and organizations, says Kimmo Hannus, Head of Business Integration Brokerage at Tieto. - Tieto is actively involved in the ecosystems of the financial sector. Together with the Federation of Finnish Financial Services, we played an active role in the specification work related to the new standard. We have also collaborated closely with the tax authorities to establish common ground rules, Hannus continues. - The implementation of the new standard will promote uniform VAT collection policies across Europe. The VAT deficit does not constitute a large problem in Finland. For Finnish companies, the most significant aspect is that implementing real-time VAT reporting at the European level would provide for a fairer competitive environment, says Pirjo Ilola, Head of Payments Standardisation and E-invoicing at the Federation of Finnish Financial Services. Pirjo Ilola notes that this new standard represents the third time the Federation of Finnish Financial Services has contributed to the creation of an ISO standard. Both Tieto and the Federation of Finnish Financial Services hope for fast and extensive adoption of the standard by the tax authorities, public sector and companies, so that its benefits can be claimed as quickly as possible. The standard is available free of charge on the ISO 20022 website (https://www.iso20022.org/trade_services_messages.page). Tieto is active in promoting digitalization in Finland and the development of the financial sector ecosystem. Among other things, Tieto has developed and implemented the Siirto payment platform, Finland's first real-time multi-banking platform for mobile payments. The company has also been strongly involved in advancing the digitalization of cash and card payment receipts as part of the TARU project (https://www.tieto.com/news/digitalization-of-receipts-can-bring-huge-savings). Tieto is involved in the ecosystems of the financial sector: Digitalization progressing in the banking sector – Tieto develops Finland's first real-time mobile payment platformhttps://www.tieto.com/news/tieto-develops-finlands-first-real-time-mobile-payment-platform-for-automatia The TARU project: Digitalization of receipts can bring huge savingshttps://www.tieto.com/news/digitalization-of-receipts-can-bring-huge-savings For further information, please contact: Kimmo Hannus, Head of Business Integration Brokerage, Tieto, +358 40 524 5203, kimmo.hannus[at]tieto.com Pirjo Ilola, Head of Payments Standardisation and E-invoicing, Federation of Finnish Financial Services, +358 20 793 4255, pirjo.ilola[at]finanssiala.fi Tieto aims to capture the significant opportunities of the data-driven world and turn them into lifelong value for people, business and society. We aim to be customers’ first choice for business renewal by combining our software and services capabilities with a strong drive for co-innovation and ecosystems. www.tieto.com 

BioGaia signs major distribution and license agreements with partner in Japan

The first agreement concerns the exclusive rights to sell probiotic supplements with BioGaia’s patented strains of Lactobacillus reuteri at drugstores, supermarkets and similar outlets. Depending on the product category, products will be sold under Kabaya, Ohayo and/or BioGaia brands and the main target segment is adults. The other agreement is an exclusive license, giving Ohayo Dairy Products the rights to use strains of Lactobacillus reuteri in food, such as drinks and dairy products. The agreements are long term and include exclusivity fees and minimum royalties over the term of the contracts, which will have a substantial effect on BioGaia’s Japanese business. Due to confidentiality, the amounts of the fees and the royalties cannot be disclosed. Nippon Kabaya Ohayo Holdings Inc. is a privately-owned company with headquarters in Tokyo and consisting of a group of 13 companies with more than 3,000 employees. Kabaya Foods and Ohayo Dairy, Japan´s 7th largest confectionary and dairy companies respectively, are both well-known brands with a strong presence in the confectionary and dairy markets. “Through these two milestone agreements with Nippon Kabaya Ohayo Holdings Inc. we have secured another trusted partner in the complex Japanese market. In addition to the marketing and sales of our supplements we look forward to the creation of innovative functional foods based on our Lactobacillus reuteri strains”, says Axel Sjöblad, Managing Director, BioGaia. Latest press releases from BioGaia 2016-11-30              BioGaia makes further investment in MetaboGen 2016-10-31              Disclosure notice in BioGaia 2016-10-25              BioGaia AB Interim management statement 1 January – 30 September 2016 This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 5 December 2016. 

Nettalliansen chooses Rejlers Embriq for IT- operation services

Through the agreement Rejlers Embriq will take responsibility for set-up and overall operation, as well as responsibility for integration support for future specialist applications that are part of Nettalliansen's digitalisation process.IT services from Rejlers Embriq – an important element of the digitalisation processNettalliansen is an expertise and purchasing alliance of small and medium-sized energy distribution companies that looks after its owners’ interests by establishing competitive and attractive shared services. The IT services that Rejlers Embriq will now supply are an important contribution to supporting the digitalisation process of the owner companies. Nettalliansen and Rejlers Embriq are already working in partnership to deliver and operate new smart electricity meters (AMS) for over 180,000 homes across Norway. Overall perspective on services“Rejlers Embriq has a good understanding of industry needs and fulfils requirements in terms of price and service quality, which is essential for us,” says Torgeir Brovold, Managing Director at Nettalliansen, and concludes: “Rejlers Embriq is way ahead when it comes to digitalisation and stands out as the most cost-effective partner for Nettalliansen.”Smart cooperation“We are pleased to be further strengthening Nettalliansen’s competitiveness,” says René Eriksen, Vice President Operations at Rejlers Embriq. “IT is becoming a very important means for achieving the objectives and overcoming the challenges facing the industry. Nettalliansen stands for smart collaboration in the power sector, and our services make modern and effective solutions available to them. This brings considerable synergies that will benefit all the owners, regardless of size or geography,” he says.  “Here at Rejlers Embriq we are delighted to be expanding our collaboration with Nettalliansen. Through our expertise within the power sector, substantial market share and solid IT expertise we can realise considerable potential together with Nettalliansen. We are looking forward to contributing in the form of flexible IT services, smart choices and strategic use of IT in the years to come,” says Thomas Pettersen, CEO of Rejlers Embriq.About the agreementThe duration of the agreement, including options, is a total of 5 years, with a value in the order of NOK 100 million for the period. The services are being set up and the first energy distribution companies will be switched to the new platform by the end of the year. About NettalliansenNettalliansen AS is an expertise and purchasing alliance owned by small and medium-sized energy distribution companies. Nettalliansen aims to look after its owners’ interests by establishing competitive and attractive shared services that contribute to increasing latitude for each local energy distribution company. Nettalliansen is experiencing strong growth and its ownership currently comprises 47 companies, with a total of 268,000 grid customers. Nettalliansen is aiming to ensure increased cost efficiency for its owners, and benefits of scale, cooperation and innovation are its focus areas. These will be the owners’ most important tools for increased competitiveness, development of new business areas and utilising the expertise of its owners through profitable coordination of resources.About Rejlers EmbriqRejlers Embriq is part of the Rejlers Group and is a business with 160 employees and an annual turnover of almost NOK 400 million. Rejlers Embriq helps to achieve business gains through digitalisation of physical infrastructure, smart choices and strategic use of IT. We design, develop and manage IT solutions and have a Nordic focus and strong roots with a presence in Oslo, Halden, Drammen, Gothenburg, Stockholm and Motala.For further information:Peter Rejler; President and CEO, email: peter.rejler@rejlers.seThomas Pettersen; CEO Rejlers Embriq, +47 950 22 323, email: thomas.pettersen@embriq.noRejlers is one of the largest engineering consultancy firms in the Nordic region. Our 2,000 experts work with projects in the areas of Building and property, Energy, Industry and Infrastructure. At Rejlers, you will meet specialist engineers with the knowledge, cutting edge expertise and energy to achieve results. We are still experiencing rapid growth and can now be found in 80 locations in Sweden, Finland and Norway. Rejlers recorded revenue of SEK 1.9 billion in 2015 and its class B share is listed on Nasdaq Stockholm.This information is information that Rejlers AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on December 5th 2016.

Lemminkäinen Corporation – Managers’ transactions

LEMMINKÄINEN CORPORATION  MANAGERS’ TRANSACTIONS  5 DECEMBER 2016 AT 9:02 A.M. LEMMINKÄINEN CORPORATION – MANAGERS’ TRANSACTIONS Lemminkäinen Corporation has received a disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Lemminkäinen Corporation made by managers and their closely associated persons. The essential content of the disclosure is as follows: Person subject to the notification requirement Name: Fideles Oy  Position: Closely associated person Person discharging managerial responsibilities in issuer Name: Forstén, Noora Position: Member of the Board of Directors Notification type: Initial Notification Reference number: 7437004WJ8GW8WTL8A35_20161202095231_2 Issuer Name: Lemminkäinen Corporation  LEI: 7437004WJ8GW8WTL8A35  Details of the transaction Transaction date: 1 December 2016 Venue: Nasdaq Helsinki (XHEL)  Nature of the transaction: Acquisition Instrument: Share ISIN: FI0009900336    Volume: 882,200  Unit price: 18,55000 Euro  Aggregated transaction Volume: 882,200  Volume weighted average price: 18,55000 Euro  LEMMINKÄINEN CORPORATIONCorporate Communications ADDITIONAL INFORMATION:General CounselJohan NyberghTel. +358 2071 54811johan.nybergh@lemminkainen.com DISTRIBUTION:Nasdaq Helsinki LtdKey mediawww.lemminkainen.com Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and 4,800 professionals we employ, we build a sustainable society. In 2015, our net sales were EUR 1.9 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com

National Test Results Released for 2016: Strong Results Show Value Added for Internationella Engelska Skolan Students Between Years 6 and 9.

Swedish education agency Skolverket has now published statistics from the 2016 national tests for middle schools. Internationella Engelska Skolan’s (IES) year 9 students have once again achieved significantly higher results than the national average. In the subject of mathematics the difference between IES and municipal schools has grown. Some 60 percent of year nine students at IES managed to achieve top grades(A-C) which compared with 35 percent of students in municipally run schools in Sweden. In Swedish, 72 percent of students in IES took top grades, against 51 percent in municipal schools. In English the difference was 97 percent against 69.As part of its quality assessment system, Internationella Engelska Skolan is now looking at the value added to its students. Irrespective of the socioeconomic composition, how much does the school help to raise the students' attainment level over a three-year period. This is a measure, which is strongly recommended by school researchers. Now, for the first time it is possible to compare the results achieved by students in grade nine in spring 2016 with the corresponding national tests that they undertook when they were in grade six in the spring of 2013. IES has found a way to statistically follow the students so that we can see the results for the exact same student body for both tests.Comparing these results to find the value added shows that Internationella Engelska Skolan has a significant positive effect on the education of students. On the national test in mathematics in year six, the gap between IES and municipal schools in terms of the percentage of students achieving top grades A-C was 11 percentage points. Three years later this gap had grown to 29 percentage points, meaning a value added by IES of 18 percentage points. In the subject of Swedish, the value added is 12 percentage points while in English the difference is one percentage point (this is because 95 per cent of IES students already received top grades in year six after most of them had studied with IES for three years).In the debate around education, it is often claimed that the positive outcomes from Internationella Engelska Skolan’s students are the result of the socioeconomic background of the students. This is said despite the fact that IES does not select its students, has many schools in poorer socio-economic areas and has a higher proportion of students with a foreign background than the average in Sweden. The new measure of value added validates that IES schools have a significant positive impact on students’ attainment. Students have shown a greater academic improvement, regardless of their background, at IES schools than they have in those run by municipalities.Damian Brunker, Head of Academics for Internationella Engelska Skolan, comments: “It is clear from the results that the calm teaching environment and the work ethic that we offer, combined with the recruitment of qualified teachers from other countries, drives positive results among students, irrespective of social background.”   For more information, please contact:   Johan Hähnel, IES’s IR ManagerTel: +46 (0)70 605 6334e-mail: johan.hahnel@engelska.se  This information is such that Internationella Engelska Skolan i Sverige Holdings II AB (publ) is obliged to publish pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the above contact, at 8:15 a.m. CET on 5 December 2016.   About Internationella Engelska Skolan  Internationella Engelska Skolan, IES, is one of the leading independent school organizations in Sweden, with 21 400 students in 30 schools during school year 2016/17. IES operates schools for students in grades 1-12. Its main focus is grade 4-9, what is often called “middle school”. Within the compulsory school system in Sweden, IES is the leading independent actor, operating nine of the ten largest free schools. IES results on the national tests in grade 9 are far above average in Sweden.Internationella Engelska Skolan was founded in 1993 and is in its 24th year of operation. It continues to be defined by three strong convictions, established by the founder, Mrs. Barbara Bergstrom: · A safe and orderly environment, where teachers can teach and students learn. · To command the English language—the key to the world. · High academic expectations. Up to half of the teaching in IES schools is performed in English, by native English speaking teachers. Over 600 teachers with qualified foreign teaching degrees are currently teaching in IES schools. They are mainly recruited from Canada, UK, USA and South Africa.IES has shown a strong and consistent growth for a number of years. Average growth during the last ten years is 19 % per year. Turnover during the latest concluded operational year, 2015/16, was 1 807 MSEK (growth of 17 % from previous year). The queue for admission for the current and coming years had 122 000 registrations as of September 30, 2016.Internationella Engelska Skolan has been listed on Nasdaq Stockholm Mid Cap with the ticker ENG since the end of September 2016. The largest shareholders of IES are TA Associates of the US, which has close affiliations to leading universities and foundations in the US, and IES’s founder Barbara Bergström. Other major shareholders at the time of the listing included Swedbank Robur funds, investment company Öresund, Norron Asset Management, the Third Swedish National Pension Fund, AMF Försäkring och Fonder and the Second Swedish National Pension Fund.

Yggdrasil Gaming strikes deal with Gaming Innovation Group

Yggdrasil’s portfolio of industry-leading games will be rolled-out across the operator’s B2C sites including its flagship online casino and sportsbook, Guts.com and Rizk.com, and its B2B network, iGaming Cloud. The operator will also gain access to Yggdrasil’s collection of in-game promotional tools, BOOST™, including the recently-launched Missions feature, as well as the social sharing tool BRAG. Fredrik Elmqvist, CEO at Yggdrasil Gaming, said: “We are thrilled to have joined forces with Gaming Innovation Group. Their deal to acquire Betit has made them one of the fastest growing and largest operators in Scandinavia, and it’s a major boon for us to be able to put our content in the hands of their players. We have rolled out some fantastic new games in recent months that we believe have really moved the needle. We remain committed to delivering our partners the best content on the market, and look forward to working more closely with GiG, particularly when it comes to gamification as it is an area where we are both excelling.” Read more at Yggdrasil (http://www.yggdrasil.com/).com TranslationThis is a translation of the Swedish original. For further information, please contact: Fredrik Elmqvist, CEO Yggdrasil Gaming, Telephone +356 996-25 104, fredrik@yggdrasilgaming.comFredrik Burvall, CEO Cherry AB (publ), Telephone +46 8-514 969 52, +46 709 279 632, Email: fredrik.burvall@cherry.se Cherry in brief  Cherry is a Swedish innovating and fast growing gaming company established in 1963. The business strategy is to create shareholder value by owning and developing fast-growing and profitable businesses within the gaming and casino industry. Cherry operates within five diversified business areas, Online Gaming through Cherry iGaming, Performance-based Marketing through Game Lounge, Gaming Technology through XCaliber. Game Development through Yggdrasil Gaming and Restaurant Casino through Cherry Spelglädje. The objective is to grow organic in combination with strategic acquisitions of fast-growing companies. Cherry employs around 900 people and has more than 4,600 shareholders. The Company’s B-shares are listed on AktieTorget.

Trading in the ByggPartner share on Nasdaq First North Premier commences today

Sverker Källgården, CEO, comments: “The listing on Nasdaq First North Premier is warmly welcomed by me and our employees. I want to welcome all new shareholders to ByggPartner and I am very pleased that a large part of the management including myself, parts of the board and approximately 120 of our employees have bought shares in the Offering. We will work hard to continue to show that ByggPartner is a company with stable profitability and growth in line with our financial goals, which goes hand in hand with our goal to create sustainable value for our customers and shareholders. Our business idea is to improve the efficiency of the construction process with simple and smart solutions with a high level of commitment.” Advisors Pareto Securities is acting as Sole Manager and Bookrunner, Avanza is Selling Agent and Gernandt & Danielsson is the legal advisor in connection with the Offering. For additional information, please contact: Sverker Källgården, CEO, ByggPartner Tel: +46 243 55 95 70 Mob: +46 70 416 97 70 Email: sverker.kallgarden@byggpartner.se  Claes Thelander, CFO, ByggPartner Tel: +46 243 55 95 44 Mob: +46 70 416 97 44 Email: claes.thelander@byggpartner.se  Jenny Rosberg, press contact Tel: +46 8 408 10 200 E-mail: jenny.rosberg@ropa.se  About ByggPartner ByggPartner is a construction company operating in Stockholm, Mälardalen, Uppsala and Dalarna. In Stockholm, Mälardalen and Uppsala the aim is to further expand and in Dalarna, the Company is one of the leading construction companies. ByggPartner offers construction works, construction services and scaffolding. For more information, see www.byggpartner.se.  Stabilization measures In connection with the Offering, Pareto Securities may carry out transactions in order to support the market price of the Company's shares at a level higher than the level that would otherwise prevail on the market. These stabilization measures may be conducted on Nasdaq First North Premier, the OTC market or in other ways, and may be conducted at any time during the period beginning on the date of publication of the final offering price and ends 30 days thereafter. Under no circumstances will transactions be carried out at a price higher than the offering price. Pareto Securities and its agents are not required to take any of these measures and it can therefore not be guarantee that any stabilization action will be taken. If actions are taken, Pareto Securities or its agents can terminate any of the measures at any time and must be completed by the end of the 30-day period mentioned above. Except for what is required by law or other regulation, Pareto Securities does not intend to disclose the extent of any stabilization measures. Certified Adviser Pareto Securities is chosen to be Certified Adviser for ByggPartner.  Important information This announcement is not and does not form a part of any offer for sale of securities. Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, New Zealand, Hong Kong, Japan, South Korea or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States. Any Offering of securities referred to in this announcement will only be made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. In any EEA Member State other than Sweden that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe,” “expect,” “anticipate,” “intends,” “estimate,” “will,” “may,” "continue," “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The information, opinions and forward looking statements contained in this communication only apply as of the date of this communication and may change without notice thereof.

Japan Patent Office intends to grant Idogen’s patent application

The Japan Patent Office has communicated its intention to grant Idogen’s Patent Application No. 2013-546073. The patent belongs to Idogen’s second patent family and broadly covers Idogen’s technology. Final grant of the patent by the JPO will take place following the payment of official fees by Idogen during the coming weeks. ”As another major market for our tolerogenic vaccine is now added to the patent portfolio, our future prospects are strengthened. The decision represents a clear increase in the value of our product portfolio.”, CEO Lars Hedbys comments. “It is very pleasing that the Japan Patent Office intends to grant this patent.” A granted patent protects the technology for 20 years from the date of PCT filing, which means that Idogen’s patent will provide protection in Japan until 2031. This patent is a member of Idogen’s second patent family and covers induction of IDO for treatment of autoimmune diseases and transplant rejection. Related patent applications in this family are pending in Canada, Europe and the USA. Idogen’s first patent family concerns additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs and is so far granted in Europe.  For additional information about Idogen, please contact: Lars Hedbys, CEO Tel: +46 (0)46-275 63 30 E-mail: lars.hedbys@idogen.com This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 5th of December 2016.

One of UK’s most experienced skippers launches exciting tuition opportunity for yacht and boat enthusiasts

Nautical enthusiasts can experience a unique opportunity to learn from one of the most experienced skippers in the UK as Seaway Deliveries expands its services to include own boat tuition. Simon Phillips, who has racked up an impressive 300,000 nautical miles ranging from the waters around Norway to the Galapagos Islands, is now available to instruct boat owners on the comfort of their own vessel as he expands his business.  Armed with a remarkable 27 trans-Atlantic crossings, including seven races, and an excellent track record for yacht racing, Phillips is set to impart his experience and passion to his customers. With an extensive list of places he’s visited by sea, boat and yacht lovers will be hard-pressed to find someone with more knowledge and insight than this skipper. As a Yachtmaster Instructor, customers can even gain formal training and certification as they learn from one of the most experienced in the business and become comfortable taking control of their own yacht. Simon Phillips, Managing Director of Seaway Deliveries, said, “Having been taken sailing on board the family yacht at only a few weeks old, I have been involved in sailing and boating all my life. There’s nothing like cruising the open waters to the next destination and the skills needed to act as a skipper of a yacht are something I love to teach. The freedom and excitement it offers our customers mean that working with them is always rewarding.” Seaway Deliveries has now been in operation for almost a decade, with its initial offering focussing on the delivery of yachts around the world. Its success has seen the business and its services rapidly grow to now include boat repairs and maintenance, skipper and crew hire and its Soft Landings packages, a bespoke service that aims to make every aspect of buying and setting out on a boat simple and stress free. It’s not just Phillips that has a high level of experience taking to the seas in the Seaway Deliveries company. The team of professional yacht skippers, first mates and crew members are carefully handpicked to ensure they maintain high standards of seamanship, professionalism and customer care and every skipper must have a minimum of 50,000 miles on a variety of yachts in differing conditions and locations around the world. The exacting standards mean customers will never be disappointed with the service they receive and have access to highly experienced professionals when they choose Seaway Deliveries. To find out more visit http://www.seawaydeliveries.com/.

Middle East Propulsion Company (MEPC) selects IFS Applications for engine MRO support

In 2012, MEPC opened its state-of-the-art, 194,000 square-foot MRO facility in Riyadh, close to the city’s King Khalid International Airport. MEPC is the sole military engine shop in the Kingdom of Saudi Arabia and provides MRO support for the Pratt & Whitney F100 engines powering the Boeing F-15 fighter aircraft operated by the RSAF. The IFS solution will allow MEPC to execute all aspects of its MRO operations, from hangar entry to exit—with integrated support for finance and HR. End-to-end visibility will extend across personal areas of responsibility, ensuring focus is kept on what is strategically important. Business intelligence is built into IFS Applications, enabling operators to analyze key performance indicators using predictive analytics to show the full impact of processes on overall MRO performance, as well as the effect a decision has on operations in real time. “Rather than continuing to use a combination of different business systems, we required a single, integrated solution to manage our complete business operations at the critically important Riyadh facility,” said Abdullah Al Omari, Chief Executive Officer at MEPC. “The 360-degree visibility provided by IFS Applications allows us to maximize maintenance efficiency and react quickly to potential performance issues, which is important in the fast-paced military support environment.” Luis Ortega, Managing Director for Middle East, Africa & South Asia at IFS added, “The selection of IFS Applications to support the MEPC facility, which is integral to military operations in the Kingdom of Saudi Arabia, demonstrates the strength of the engine MRO capability in IFS Applications. The RSAF is one of the most advanced fighting forces in the world, and we are delighted to be supporting MEPC with our market-leading engine MRO solution to keep its aircraft available and operational around the clock.”

Saab Receives Order for Carl-Gustaf M4

The new version has all the effectiveness and versatility of the proven Carl-Gustaf system but with enhancements. These include a lightweight design (weighing less than 7 kg), a round counter and intelligent features, such as compatibility with future innovations like the intelligent sighting systems and programmable ammunition, which collectively offer significant operational improvements for the soldier. “With the M4 version the customer will have a weapon with the latest technology and with improved ergonomics which will give them an increased tactical flexibility to deal with any situation on the battlefield”, says Görgen Johansson, head of Saab business area Dynamics. With this order, Saab has secured a new Carl-Gustaf customer and also its fourth customer of the new M4 system since the market debut in late 2014. In 2015, Saab received the first order of the new Carl-Gustaf M4 from the armed forces of the Slovak Republic. In addition, the system was acquired by two other countries for evaluation and qualification purposes. The industry’s nature is such that depending on circumstances concerning the product and customer, further information regarding the customer will not be announced. Saab’s world-leading weapon system Carl-Gustaf has a long and distinguished service history all around the world. It has been successively modernised and enhanced to meet the changing requirements of its users.For more information and videos (A- and B-rolls) for editorial use, see attached links:http://saabgroup.com/Media/media-videos/ For further information, please contact: Saab Press Centre, Helena Dahlberg, Media Relations Manager +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Classic Portuguese revives heritage knitwear process from the hilltops of Serra da Estrela, forming collection refined through time

Whether it is a drop of fine wine or a hide of full-grain leather, there are certain things in life that owe their iconic and desirable status due to an ability to hold and even improve in quality as time passes by. In addition to tangible artefacts, certain processes that originate from years ago are also considered the premium choice above modern techniques as they remain relevant in newer ages, re-affirming the method year upon year. New artisanal menswear brand, Classic Portuguese uses the timeless, traditional manufacturing techniques from Serra da Estrela, its region of origin, to form its inaugural ‘Serra’ collection of luxury knitwear that is refined through time.   While the rural hilltops of Scotland or Australia may be more commonly associated with producing premium quality wool, Serra da Estrela, the highest mountain range in Portugal, is the industry’s ‘best kept secret’. Although it is a wild, rugged yet beautiful landscape, the natural environment at Serra da Estrela led to the development of the ‘Wool routes’ that attracted the best shepherds, wool processers and traders in the industry some centuries ago. A thriving wool trade was soon born, still existing now after hundreds of years. This rare culture, allowed manufacturing and dyeing knowledge to be preserved and improved throughout the centuries, creating an unparalleled hub for wool manufacturing.  Classic Portuguese uses this inspiration to create its heritage knitwear collection, offering a sense of timeless style embedded into each garment through the iconic textiles and practises that are used. Robin Da Silva Laires, Founder of Classic Portuguese said, “Technological developments have done wonders for many industries but there are certain areas, such as knitwear, where classic techniques simply offer the best solution for producing the highest quality garments. The striking mountain range in Serra da Estrela has formed a flourishing woollen trade, offering space for sheep to graze and wool to be processed by the hands of expert artisans. We respect the time-old traditions that have moulded this area, lying at the heart of our brand and the clothing we create. As well as using the local manufacturing methods, our on-going inspiration from the region can also be seen in the design of each sweater, with the colour palette used in each of our three debut pieces paying homage to a particular aspect of the Portuguese landscape.” A fine blend of merino wool and cashmere forms the basis of each well fitted sweater in the Serra collection, produced with gentle ribbing on the hem, cuffs and neckline to finish every piece with subtle luxury. The new range from Classic Portuguese comprises of a capsule collection of three sweaters, available in Alpine, Ocean and Terracotta shades. While the time-old traditions that inform the new, heritage knitwear brand effortlessly results in a high-quality selection of sophisticated classic clothing, Classic Portuguese also proudly presents itself as an ethical brand through the sustainable, historic wool-craft processes that it uses. To find out more and to view the full Serra collection, visit www.classicportuguese.com Or join the conversation online. Facebook: /classicportuguese Twitter: @classicportu Instagram: @classicportuguese 

Lemminkäinen Corporation completes the tender offer of its outstanding hybrid bond issued on 11 March 2014

LEMMINKÄINEN CORPORATION  STOCK EXCHANGE RELEASE  5 DECEMBER 2016 AT 12:15 P.M LEMMINKÄINEN CORPORATION COMPLETES THE TENDER OFFER OF ITS OUTSTANDING HYBRID BOND ISSUED ON 11 MARCH 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Lemminkäinen Corporation completes the partial repurchase of its hybrid bond (ISIN FI4000086665) issued on 11 March 2014. The company has agreed to repurchase notes to a nominal amount of EUR 34.8 million in exchange for cash which represents 49.7 per cent of the original EUR 70 million hybrid bond issued in 2014. All tenders from noteholders have been accepted in full. The purchase price for the notes is 107.85 per cent, amounting to EUR 107,850 per each EUR 100,000 nominal amount of the notes. Accrued and unpaid interest until the settlement date on 9 December 2016 will also be paid in accordance with the terms and conditions of the tender offer memorandum. The repurchased notes will be annulled, after which EUR 35.2 million of the hybrid bond issued in 2014 will remain outstanding. The company is entitled to redeem it on 30 March 2018 at the earliest. A hybrid bond is an instrument which is subordinated to the company’s other debt obligations and which is treated as equity in the IFRS financial statements. The hybrid bond does not confer to its holders the rights of a shareholder and does not dilute the holdings of the current shareholders. Nordea Bank Finland Plc is acting as the exclusive dealer manager and tender agent for the tender offer. LEMMINKÄINEN CORPORATIONCorporate Communications ADDITIONAL INFORMATION:Ilkka Salonen, CFOTel. +358 2071 54524ilkka.salonen@lemminkainen.com  DISTRIBUTION:Nasdaq Helsinki LtdKey mediawww.lemminkainen.com  Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and 4,800 professionals we employ, we build a sustainable society. In 2015, our net sales were EUR 1.9 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com

THQ Nordic AB (publ) Acquires Multiple Franchises - new additions to the THQ Nordic portfolio

Karlstad (Sweden), December 5: Today, THQ Nordic announced that an asset purchase agreement with Mobile Gaming Studios Ltd. and Enigma Software Productions S.L. has been closed. Here is an extract of the acquired franchises and brands: · Sphinx (and the Cursed Mummy); Mobile Gaming Studios Ltd. · War Leaders: Clash of Nations (Enigma Software Productions S.L.) · Legends of War (Enigma Software Productions S.L.) Lars Wingefors, founder and Group CEO, comments: “Due to our love for these types of games they were natural acquisition targets, however this financially a smaller acquisition it adds up to our portfolio” said Lars Wingefors Group-CEO, THQ Nordic. “Moreover, we also got a lot of messages from fans that encouraged us to add them to our portfolio. Among these titles, Sphinx (and the Cursed Mummy) is very well suited for the Nintendo audience – which we love to support. We are excited for Nintendo Switch, Nintendos new platform, and already have two other projects in development for it”, Wingefors continues. Sphinx (and the Cursed Mummy) is a third person action-adventure video game inspired by the mythology of Ancient Egypt. It was originally released for Xbox, PlayStation 2 and Nintendo GameCube. War Leaders: Clash of Nations is a turn-based global strategy game bundled with a real-time tactics game mode for PC. Legends of War is a turn-based strategy video game series franchise created in 2010. It was released for PlayStation 3, Xbox 360 and PlayStation Portable. For additional information, please contact:  Lars Wingefors, Group CEO Tel: +46 708 471 978 E-post: lwingefors@thqnordic.com About THQ  THQ Nordic acquires, develops and publishes PC and console games for the global games market. The core business model consists of acquiring established but currently underperforming franchises and successively refining them. The Company focuses on owning its own franchises and developing and publishing these, and as of 31 October 2016 had around 75 owned franchises in the portfolio. The Company has a global presence, with its Group head office in Karlstad, Sweden and its operational head office in Vienna, Austria. As of 31 October 2016 the Company had four internal game development studios – two in Sweden, one in Germany and one in the US – and contracts with 19 external game studios in a number of different countries. As of the same date the Company employed more than 370 people, of which around 30 personnel within the publishing business, around 70 personnel within internal game development and more than 270 contracted external game developers. THQ Nordic’s shares are listed at Nasdaq First North with FNCA Sweden AB as its Certified Adviser. This information is information that THQ Nordic AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 CET on 5 December 2016.

3odel’s innovative 3D visualisation tool for property data wins Hack the Office

3odel’s innovative 3D visualisation tool for property data wins Hack the Office 3D visualisation model for property data won the first Hack the Office contest in the Nordic property sector. The winning ideas were announced at Slush 2016 on 1 December 2016. The winning 3D model offers a new way of visualising property data, and it was created by Jere Laitala and Tim Borovkov at 3odel. The second prize was awarded to Instafix, and GoFaraday placed third.  The winners were selected by a jury of experts from Caverion and Granlund. The judges praised the winning idea for its effective visualisation and excellent potential for further development into a support tool for property management. Instafix’s idea was based on the slogan “Make maintenance Great Again”, and GoFaraday focused on cutting down on the use of electricity at offices.   Digitisation increases the amount of property data Technology is becoming an increasingly important element in built environments, and digitisation enables collecting property data at an unforeseen rate. At the moment, the information is used for managing energy consumption and conditions at properties, and to support property maintenance. “As per its strategy, Caverion wants to promote the use of property data and commercialise it better. Integrated building technology systems require expertise in a number of different fields. We need new innovations in order to commercialise the data we have collected, and we wanted to challenge start-ups to take on the task, says Ville Tamminen, Senior Vice President, Sales and Marketing at Caverion. Caverion and Granlund were the main partners at the first Hack the Office event in the Nordic property sector. The event featured an international group of start-up developers, who spent 48 hours creating innovative automation applications for smart office buildings. Four teams qualified to move on to the second round. 

Allianz Global Assistance Partners with GradGuard for Tuition Insurance

Allianz Global Assistance, a leading consumer specialty insurance provider and GradGuard™, a leading provider of student protection programs at more than 200 colleges and universities, have formed a partnership to provide Allianz Tuition Insurance to higher education institutions across the nation. The companies are working together to protect the nearly $500 billion investment that 21 million college students or their parents make annually in higher education.   Allianz Tuition Insurance provides a practical way for families to safeguard their tuition in case a student must withdraw from school due to a reason covered by the policy, such as a covered illness or injury.  Allianz Tuition Insurance also helps schools provide a better withdrawal experience for students by providing reimbursement when schools may not.  Allianz Tuition Insurance (http://www.allianztuitioninsurance.com/) offers a range of plans to protect both in-state and out-of-state non-refundable college tuition, housing and other fees in the event that a student withdraws from school for a covered illness, injury, psychological/mental disorder, or other reasons. One of the plans provides coverage for almost any unforeseen reason that may cause a student to leave school.* Allianz Tuition Insurance must be purchased prior to the first day of the semester and three different plans (http://www.allianztuitioninsurance.com/tuition-insurance-plans) are available, starting at only $29.95 per semester. The insurance also includes Allianz Global Assistance’s proprietary Student Life Assistance, a 24/7 service that assists families in the event of an emergency. A recent survey of financial advisors conducted by an independent firm and commissioned by Allianz reports that nearly eight in 10 (78 percent) financial advisors say they would recommend tuition insurance for students taking out loans while more than seven in 10 (72 percent) say they would recommend it for first-year college students. “College tuition is one of the largest investments that consumers will make in their lifetime,” said Joe Mason, chief marketing officer of Allianz Global Assistance USA. “A significant number of students will have to leave school unexpectedly due to an illness, injury or serious psychological issue sometime during their college career.  Allianz Tuition Insurance can refund lost tuition and fees, offering students a financial lifeline and colleges with a student-friendly solution for withdrawals.” “Working closely with Allianz Global Assistance will help GradGuard fulfill our mission to protect the investment that students and families make in higher education,” said John Fees, co-founder of GradGuard™. “We are confident that colleges and universities and the families they serve will be pleased with the innovative approach that Allianz Tuition Insurance brings to helping students protect their investment in a higher education.” GradGuard, a service of Next Generation Insurance Group LLC, is a leading provider of student protection programs at more than 200 colleges and universities and an authority at designing and implementing student benefit programs that help schools to attract and retain students.  Since 2008, GradGuard’s tuition and renters insurance programs have helped more than 600,000 students protect their investment in a higher education. Please visit GradGuard.com to learn more about how we fulfill our mission to protect the investment students and their families are making in a higher education. Learn more at GradGuard.com/highered (https://www.gradguard.com/highered). Allianz Global Assistance USA Allianz Global Assistance USA (AGA Service Company) is a leading consumer specialty insurance and assistance company.  We serve 21 million customers annually and are best known for our Allianz Travel Insurance plans. In addition to travel insurance, Allianz Global Assistance USA offers tuition insurance, event ticket protection, registration protection for endurance events and unique travel assistance services such as international medical assistance and concierge services. The company also serves as an outsource provider for in-bound call center services and claims administration for property and casualty insurers and credit card companies. To learn more about Allianz Tuition Insurance, visit AllianzTuitionInsurance.com (http://www.allianztuitioninsurance.com/) or call 1.888.427.5045.  Like us on Facebook at https://www.facebook.com/AllianzTuition  *Terms, conditions, and exclusions apply. Plans are available only to U.S. residents. Not all plans are available in all jurisdictions. For a complete description of the coverage and benefit limits offered under your plan, carefully review your declarations page and Certificate of Insurance/Policy. Insurance coverage is underwritten by Jefferson Insurance Company (NY, Administrative Office: Richmond, VA), rated “A+” (Superior) by A.M. Best Co., under Jefferson Form No. 107-P series. Allianz Global Assistance and Allianz Tuition Insurance are brands of AGA Service Company. AGA Service Company is the licensed producer and administrator of these plans and an affiliate of Jefferson Insurance Company. The insured shall not receive any special benefit or advantage because of the affiliation between AGA Service Company and Jefferson Insurance Company. Non-insurance benefits/products are provided and serviced by AGA Service Company.

Saab Receives Contract for Components to the U.S. Marine Corps’ Ground/Air Task-Oriented Radar Program

G/ATOR will provide the U.S. Marine Corps with a single radar type that performs air surveillance, air defense, ground weapon locating and air traffic control missions. It is the first ground-based multi-mission active electronically scanned array (AESA) radar to be developed by the U.S. Department of Defense. “With this contract, Saab continues to play a significant role in providing this capability to the U.S. Marine Corps. Saab’s proven ability to provide innovative radar technology and highly capable solutions, on our own as well as in partnership with US primes, remains a strong foundation of our company and further supports our leading position as a supplier of radar and sensor systems in the global market,” says Erik Smith, President and CEO of Saab Defense and Security USA. The contract awarded by Northrop Grumman Corporation, prime contractor to the U.S. Marine Corps for the G/ATOR program, covers the delivery of major subsystems and assemblies, as well as software, for the next nine Low Rate Initial Production (LRIP) units. The Saab developed and built assemblies will be integrated by Northrop Grumman into the Lots 3-5 G/ATOR systems which will be delivered to the U.S. Marine Corps starting in 2018. In 2016 Saab successfully completed delivery of the first six systems under a prior contract for LRIP Lots 1 and 2. Saab is a teammate to Northrop Grumman for the U.S. Marine Corps AN/TPS-80 program. The award to Saab includes priced options for additional sets of assemblies as well as associated spares. For further information, please contact:Saab Press Centre+46 (734) 180 018presscentre@saabgroup.com Saab North America Media Contact:Mr. John A. Belanger, V.P., Head of Communications, Saab North America, Inc. john.belanger@saabgroup.comTel: +1 (703) 406-7905 www.saabgroup.com  www.saabgroup.com/YouTubeFollow us on Twitter: @saab (https://twitter.com/saab) Saab Defense and Security USA LLC (SDAS) delivers advanced technology and systems to United States armed forces and other government agencies. Headquartered in Sterling Virginia, the company has business units and local employees in four states. SDAS is a wholly owned subsidiary of the Saab Group. Saab serves the global market with world-leading products, services and solutions within military defense and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs.

Article from Placeringsguiden #12 December 2016: New stock market winners when banks are redefined / Nya börsvinnare när bankerna stöps om

The article gives a good description of the situation on the Swedish market and the changes that are taking place. The most important nisch actors are being described and among them are DDM Holding. "… DDM Holding listed on First North have found their own niche and specialized as investors in and managers of consumer receivables in Eastern Europe." “…management sees strong growth potential of loan portfolios to acquire in the region". Please find the full article in the magazine Placeringsguiden (is to be found in the magazines web shop www.privataaffarer.se/butik or app Placeringsguiden and will be sent to the subscribers of the magazine). In SwedishNya börsvinnare när bankerna stöps om Nyhetsmagasinet Placeringsguiden har i sitt decembernummer en omfattande kartläggning av den svenska bankmarknaden. “Storbankerna är under press av extremt låg ränta, nya regler och en snabb förändring av teknik och kundbeteenden. Men det öppnar även för uppköp och en rad framgångsrika nischaktörer som har kommit ut på börsen”. Artikeln ger en god beskrivning av situationen på den svenska marknaden och de förändringar som sker. De viktigaste nischaktörerna beskrivs i artikeln och bland dessa finns DDM Holding. ”… DDM Holding på First North har hittat en egen nisch och specialiserat sig som investerare i, och förvaltare av, konsumentfordringar i Östeuropa.” ”…ledningen ser stark tillväxt med möjliga låneportföljer att förvärva i regionen”. Hela artikeln finns i Placeringsguiden #12, december 2016, (som säljs tidningens webbshop www.privataaffarer.se/butik eller deras app Placeringsguiden samt distribueras till tidningens prenumeranter).

Trigon Agri A/S announces the completion of the debt to equity conversion

Trigon Agri A/S announces that it has successfully completed the conversion of its SEK 350,000,000 11% Bond Loan into equity. Comment from the Chairman of the Board, Mr. Johannes Bertorp: "I am very proud to announce that we have now finalised the full debt for equity swap. Without the debt burden, the company can now develop its assets and focus on the profitable farming operations. I would like to thank all involved stakeholders and advisors for a good cooperation during these tough times and welcome our new shareholders". Following such conversion 1,598,730,000 new shares each of nominally EUR 0.01, corresponding to an aggregate nominal amount of EUR 15,987,300, have been issued and delivered to the accounts of the bondholders of Trigon Agri A/S who have now become the shareholders of Trigon Agri A/S. As of today, the total number of shares issued by Trigon Agri A/S is 1,728,357,479 each of nominally EUR 0.01 corresponding to an aggregate nominal amount of EUR 17,283,574.79. The share capital increase and the amended Articles of Association have been registered with the Danish Business Authority. All new shares will be listed and admitted to trading on Nasdaq OMX Stockholm shortly after they have been delivered to the shareholders account. Further information to the shareholders entitled to warrants The shareholders that are entitled to warrants are reminded that the acceptance period for warrants has commenced. The forms containing detailed instruction on further actions necessary for acceptance of the warrants shall be sent to the shareholders registered in the register of shareholders (the forms will include pre-printed information to the extent possible). The blank acceptance form both in Swedish and English languages is available for download here: http://www.trigonagri.com/investor-relations/warrants/. Investor enquiries: Mr. Simon Boughton, CEO of Trigon Agri A/S, Tel: +372 6191 500, E-mail:  mail@trigonagri.com About Trigon Agri A/S Trigon Agri A/S is an integrated soft commodities production, storage and trading company with operations in Ukraine, Russia and Estonia. Trigon Agri A/S shares are traded on the main market of Nasdaq Stockholm. For subscription to Company announcements please contact us: mail@trigonagri.com If you do not want to receive Trigon Agri A/S press releases automatically in the future please send an e-mail to the following address: unsubscribe@trigonagri.com. This information is information that Trigon Agri A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17:00 CET on 5 December 2016.

Trigon Agri A/S: Major Shareholder Announcement

Following the conversion of Bond Loan into equity in Trigon Agri A/S (CVR no. 29801843) ("Trigon Agri") on 5 December 2016, Trigon Agri hereby pursuant to Section 29 of the Danish Securities Trading Act announces receipt of the following major shareholder’s notifications: Trigon Agri A/S has received the following information: Mr. Gaurav Dhawan now indirectly through Phoenix Commodities Pvt. Ltd (company reg. no. 464110) owns 207,834,900 shares and voting rights in Trigon Agri, corresponding to 12.02% of the total share capital and of the total voting rights of Trigon Agri. Gaurav Dhawan controls Phoenix Commodities Pvt. Ltd who is the direct owner of the shares. Mr. Mats Nilsson now directly holds 126,050,000 shares and voting rights in Trigon Agri, corresponding to 7.29% of the total share capital and of the total voting rights of Trigon Agri. Mr. Joakim Johan Helenius now directly and indirectly via Trigon Capital AS (company reg. 10179709) holds shares and voting rights corresponding to less than 5% of the total share capital and of the total voting rights of Trigon Agri. In addition to his direct shareholding, Joakim Johan Helenius controls Trigon Capital AS, who is also a direct shareholder in Trigon Agri. Mr. Henrik Østenkjær Lind now indirectly through Lind Invest ApS (CVR no. 26559243) and Lind Value ApS (CVR no. 31767156) holds less than 5% of the total share capital and of the total voting rights of Trigon Agri. Lind Value ApS, the direct shareholder and owner of the shares, is controlled by Lind Invest ApS which, in turn, is controlled by Mr. Henrik Østenkjær Lind. Hunter Hall International Limited (ACN 059 300 426) now indirectly via Hunter Hall Investment Management Limited (ACN 063 081 612), holds shares and voting rights corresponding to less than 5% of the total share capital and of the total voting rights of Trigon Agri. Hunter Hall International Limited controls Hunter Hall Investment Management Limited (ACN 063 081 612), its wholly owned subsidiary company.  Hunter Hall Investment Management Limited has the power to control the exercise of the right to vote attached to the shares, and the power to exercise control over the disposal of the shares as Responsible Entity of various managed investment schemes registered in Australia. Sparinvest S.A via ID Sparinvest, Filial af Sparinvest S.A., Luxembourg ("Sparinvest") now holds 418,867,260 voting rights corresponding to 24.235 % of the total voting rights of Trigon Agri. Further information: Sparinvest S.A. is a UCITS and AIFM approved management company/alternative fund manager and portfolio manager for the following: Investeringsforeningen Sparinvest (a Danish UCITS) from 5 December 2016 owning 97,979,310 shares corresponding to 5.669% of the issued shares in Trigon Agri. Sparinvest SICAV (a Luxembourgish UCITS) from 5 December 2016 owning 60,431,994 shares corresponding to 5.611% of the issued shares in Trigon Agri. Sparinvest SICAV-SIF (a Luxembourgish SIF) from 5 December 2016 owning 120,224,496 shares corresponding to 6.956% of the issued shares in Trigon Agri. Undisclosed discretionary mandates from 5 December 2016 owning totally 5.999% of the issued shares in Trigon Agri A/S, none of the single mandates exceeding the threshold of 5% for disclosure of shareholding. Sparinvest exercises the voting rights on behalf of the funds listed above. Ownership structure of Sparinvest Companies: ID Sparinvest is the Danish branch of the Luxembourg based management company/alternative fund manager called Sparinvest S.A. which manages UCITS and AIFs in Luxembourg and Denmark. Sparinvest S.A. is 100% owned by the Luxembourg based SE company called Sparinvest Holding SE. Sparinvest Holding SE is owned by 60 financial companies ranging from banks to insurance companies and pension funds. Investor enquiries: Mr. Simon Boughton, CEO of Trigon Agri A/S, Tel: +372 6191 500, E-mail:  mail@trigonagri.com About Trigon Agri Trigon Agri is an integrated soft commodities production, storage and trading company with operations in Ukraine, Russia and Estonia. Trigon Agri’s shares are traded on the main market of Nasdaq Stockholm. For subscription to Company announcements please contact us: mail@trigonagri.com If you do not want to receive Trigon Agri press releases automatically in the future please send an e-mail to the following address: unsubscribe@trigonagri.com. This information is information that Trigon Agri A/S is obliged to make public pursuant to the Danish Securities Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 21:30 CET on 5 December 2016.

Nordic Nanovector: Betalutin® in combination with rituximab demonstrates synergistic anti-tumour effect in preclinical non-Hodgkin lymphoma model

Oslo, Norway, 6 December 2016 Nordic Nanovector ASA (OSE: NANO) announces that it has presented a poster describing the synergistic therapeutic effect of Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab in a preclinical model of non-Hodgkin lymphoma (NHL) (abstract 4189). The new data was presented at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA). These results build on previously presented data showing that treatment with Betalutin® increased binding of rituximab to NHL cells and uptake of rituximab in NHL tumours. The study found that Betalutin® in combination with rituximab showed a stronger anti-tumour effect compared to control groups and each of the treatments alone. The median survival time of mice given the combination was statistically significantly longer (>222 days, p < 0.05) than the survival of those receiving either of the treatments alone (31 days with rituximab and 60 days with Betalutin®). Betalutin® targets the CD37 antigen on NHL cells while rituximab targets CD20, and is the current gold standard therapy for NHL. Jostein Dahle, Nordic Nanovector’s Chief Scientific Officer, commented: “These preclinical results with Betalutin® in combination with rituximab are very encouraging and suggest that there is a strong synergistic effect against non-Hodgkin lymphoma tumours. Should this effect be confirmed in clinical studies, it would represent a very promising development and an important new dual immunotherapy approach for the treatment of NHL.” The poster (abstract 4189) was presented on Monday, 5 December 2016, between 6:00PM-8:00PM Pacific Standard Time (Oslo: Tuesday 6 December, 3:00AM–5:00AM CET) and is available at: http://www.nordicnanovector.com/product-info/scientific-posters. For further information, please contact: IR enquiries: Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601 Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector: Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Catella launches a new parking fund – Catella Parken Europa

The Catella Parken Europa fund aims to attain an equity target of EUR 200 million and will invest at least 70% in the core countries of Central Europe. In addition, up to 30% of the portfolio will be invested in other European countries, such as Portugal, the Czech Republic and Poland. The fund is designed exclusively for institutional and semi-professional investors, who will be able to participate from EUR 5 million and upward. “Parking as an asset class is still often underestimated, although car parks have a higher average initial rate of return than office or retail properties. The targeted size of the individual properties we are aiming for in the fund is EUR 5 million or higher,” says Henrik Fillibeck, Managing Director of Catella Real Estate. The properties are being selected by Catella’s Dutch partner Orange Investment Managers, which focuses on the acquisition and asset management of parking garages in Europe. The company is headed by two partners with a combined 25 years of experience in the parking investment business, and who have acquired parking garages across Europe worth more than EUR 800 million. “Parking has matured into an established investment alternative in recent years. Throughout Europe, there are around 48,000 parking garages in 28 EU member states. The market is expected to grow further in years to come because car sharing, electric cars and highly automated driving will increase demand for paid-for parking space. Parking space increasingly comes at a premium, especially in city centres, at airports and around hospitals, while parking charges are rising significantly faster than inflation. In addition, long leases mean that parking garages enjoy low levels of volatility and stable income,” says Thomas Beyerle, Head of Group Research at Catella. “The Catella Parken Europa fund will further contribute to significantly strengthening our market position as a niche provider of open-ended investment funds. Together with our experienced partner, we want to build a broadly diversified portfolio of lucrative parking garages all over Europe for our investors, with a balanced risk-reward profile,” says Henrik Fillibeck.

Wihlborgs signs lease with Folktandvården Skåne in Lund

The premises will comprise a large modern clinic with 38 treatment rooms for general and specialist dentistry; a knowledge arena focused on research, developing care and training; and Folktandvården Skåne’s head office. Occupancy is scheduled for 1 April 2018 and the lease extends for 15 years. “Folktandvården are making an exciting investment and we are delighted that they have chosen to partner with Wihlborgs. These premises are ultra-modern in a strategic location adjacent to Lund Central Station,” says Anders Jarl, CEO of Wihlborgs Fastigheter. “Daily contact and proximity will increase between the clinic, research and management, which means that clinical research project findings can be incorporated more rapidly in practical healthcare operations. This will benefit all residents of Skåne,” explains Marika Qvist, CEO of Folktandvården Skåne. Demand for modern office space in central Lund is substantial and negotiations are ongoing with a number of interested parties for the remaining space at Posthornet. The property has a total of around 11,000 m2 of office space which will be ready in spring 2018. The building will have a clear environmental profile with a roof-top solar cell facility and environmental certification to SGBC Gold. More information is available at www.wihlborgs.se/en/projects/lund/posthornet-lund/ (https://www.wihlborgs.se/en/projects/lund/postterminalen-lund/) Wihlborgs Fastigheter AB (publ)

Jörgen Lantto proposed to join myFC’s board of directors and invest in myFC

Björn Westerholm, CEO of myFC and Jörgen Lantto The Nomination Committee and the Board of myFC Holding AB, have communicated that they will support the election of Jörgen Lantto as a new member of the board of myFC Holding AB during the extraordinary shareholders meeting on December 21, 2016. The Board also supports the motion to issue not more than 263 158 shares through a directed shares program to Jörgen Lantto without the preferential right of existing shareholders. This means an increase in the share capital of not more than 15 389,36 Swedish krona, whereby 5 MSEK before issue cost is added to the company. Payment will be made in connection with the election to the Board. The price for the directed shares will be based on the price at market closing time, minus 5,9 percent, on December 5, 2016 for myFC. Lantto was most recently CEO of Fingerprint Cards AB, a Swedish high-technology company developing and selling biometric systems for smartphones and other applications. Fingerprint Cards is traded on Large Cap, Nasdaq OMX. During Lantto’s leadership, Fingerprint Cards established a world-leading position in fingerprint sensors and during 2015 the company grew its revenues more than 1100 percent. In addition to Fingerprint Cards, Lantto has an extensive background in the telecom industry, primarily in the Ericsson group. "I am very pleased that myFC’s nomination committee and the board have proposed for me to join the board of directors of myFC Holding AB. myFC has during an extended period developed a technology that has the potential to help consumers get uninterrupted access to power in smartphones and other devices, thereby also contributing to a sustainable society. I am really looking forward to supporting myFC’s management in enabling a global expansion of the company, its technology and products, with the ambition to create yet another leading Swedish technology company in a truly global market", says Jörgen Lantto. "Jörgen has exceptional knowledge and experience from the telecom and component industry through a number of leading roles in Fingerprint Cards, Ericsson and other companies.In these roles, he has had profound relations with mobile operators and smartphone manufacturers with the associated world-wide ecosystems. As previously announced, myFC signed a multiyear framework agreement for the delivery of myFC’s fuel cell technology to China, while also receiving an initial order. We are now planning to ramp up our capability of meeting demand from existing customers, and we will also further develop our business model and product portfolio to further exploit our technology’s potential. This means that we are entering a very exciting phase where Jörgen’s previous experiences become highly relevant, and I am really looking forward to starting this work together with him", says Björn Westerholm, CEO of myFC. "I am very pleased that Jörgen Lantto has elected myFC Holding AB to be the only public company he sees fit to currently join. As a member of the board of directors, I am convinced that Jörgen’s input and direction will be of great use for us now that we are about to create and execute upon our future strategy on a global level", says Carl Palmstierna, Chairman of the Board of myFC Holding AB. For press inquiries, please contact: My Ernevi, Head of Marketing Email: my.ernevi@myfc.se  (my.ernevi@myfc.se%C2%A0)Phone: +46 (0) 703 83 63 43 This information is information that myFC is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:55 CET on 6 of December 2016.  

Mycronic adjusts the outlookupwards for full year sales in 2016

Täby, 6 December, 2016 - Mycronic AB (publ), today adjusts the outlook upwards for full year sales in 2016 to the level of SEK 2,200 million, excluding effects from acquisitions.   The background for the upward adjustment is a combination of earlier delivery of a Prexision-80 mask writer, an order received in December 2015, the change in product mix within Mycronic’sboth business areas as well as currency effects.The current assessment for sales in 2016 has been at the level of SEK 1,900 million, excluding effects from acquisitions.Mycronic’s mask writer Prexision-80 is an advanced system for cost-effective manufacturing of the most advanced photomasks for display applications. At the time of the order it was agreed with the customer that delivery would take place during first quarter of 2017 at the latest. A successful completion of the project and agreement with the customer has enabled delivery in December 2016. Contacts at Mycronic:Lena Olving                         VD och koncernchef            Tel: +46 8 638 52 00lena.olving@mycronic.com                                         Per EkstedtCFO                                   Tel: +46 8 638 52 00per.ekstedt@mycronic.com                                         About Mycronic ABMycronic AB is a Swedish high-tech company engaged in the development, manufacture and marketing of production equipment with high precision and flexibility requirements for the electronics industry. Mycronic headquarters are located in Täby, north of Stockholm and the Group has subsidiaries in China, France, Germany, Japan, Singapore, South Korea, the Netherlands, United Kingdom and the United States. For more information see our web site at: www.mycronic.com  Mycronic AB (publ) is listed on NASDAQ Stockholm, Mid Cap: MYCR.  The information is of the type that Mycronic is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the contact persons stated above, on 6 December, 2016, at 8.00 am.

BADGER EXPLORER ASA – PRIVATE PLACEMENT COMPLETED

Reference is made to the stock exchange release from Badger Explorer ASA (the "Company") published yesterday, 5th December 2016 regarding the contemplated private placement of shares in the Company.The Company announces today that it has raised NOK 45 million in gross proceeds through a private placement consisting of 360 million new shares (the "Private Placement") with a subscription price of NOK 0.125.ABG Sundal Collier ASA acted as manager (the "Manager") in the Private Placement.The new shares allocated in the Private Placement will be issued subject to approval by an Extraordinary General Meeting to be held on or about 9th January 2017 (the "EGM").Notification of conditional allotment and payment instructions in the Private Placement will be sent to the applicants today by the Manager. The payment date for the Private Placement is expected to be on or about 12th January 2017, but not before the EGM has approved the Private Placement. Registration and delivery of the shares is expected to take place on or about 16th January 2017.Following and subject to completion of the Private Placement, the Company will have an issued share capital of NOK 47,317,161 divided into 378,537,288 shares, each with a par value of NOK 0.125.The following primary insiders were allocated shares in the Private Placement:CFO Gunnar Dolven, through his wholly owned investment company Dalvin Rådgivning AS: 2,400,000 shares. Shareholding after the transaction: 2,834,872 shares.CEO Roald Valen: 2,400,000 shares. Shareholding after the transaction: 2,400,000 shares.Chairman of the Board of Directors Marcus Hansson and close associates: 20,000,000 shares. Shareholding after the transaction: 20,616,668 shares representing 5.45% of the shares.Stavanger, 6th December 2016For further information, please contact:Gunnar Dolven, CFO, cell phone +47 908 53 168Marcus Hansson, COB, cell phone +44 782 4460 691Important information:The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia).This release is an announcement issued pursuant to legal information obligations, and is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Manager assumes any responsibility in the event there is a violation by any person of such restrictions.The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Manager is acting for the Company and no one else in connection with the Private Placement and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement and/or any other matter referred to in this release.Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Gant gains more efficient IT operations with solution from Proact

The international clothing brand Gant has updated its IT infrastructure with support from Proact. Gant, with its corporate headquarters and enterprise IT management in Sweden, had previously implemented a virtualised environment in its data centres, using VMware software platforms. The company has recently taken this initiative one step further by updating IT infrastructure with Proact’s assistance, complemented by consulting and support services. “We now operate a fully redundant environment, which delivers higher system availability and makes our business operations less vulnerable,” says Kenneth Karlsson, Global IT Infrastructure Manager at Gant. “The new infrastructure is also easier to manage, supporting our efforts for more efficient IT operations.” Gant operates its own data centres in three European countries and in the United States, all of which have implemented the new solution. In the UK, a new converged solution has been installed to replace the entirety of the former systems environment, including servers, storage and networking. Gant has also deployed a new backup solution using snapshot technology, and backup management has been centralised to Sweden. “We have a long-term relationship with Gant, a company with a well-designed strategy to actively engage inhouse IT resources and skills to develop its business,” says Lena Eskilsson, Managing Director Proact IT Sweden AB. “Gant has demonstrated how an international enterprise can successfully build and manage a high-performance, state-of-the-art IT infrastructure.”

NTTBP Appoints Clavister to Secure Its Public Wi-Fi Services Network in Japan

Clavister (Nasdaq: CLAV), a supplier of high-performance network security, today announced that NTTBP, Japanese provider of carrier grade Wi-Fi service, highly customized Wi-Fi services for transportation facilities, vehicles, convenience stores and local government, high-density WiFi in studiums and convention centers, and value added services, and a group company of NTT Group, a leading company in the communications industry, has selected Clavister and its integrator partner MIRAIT to implement security on NTTBP’s extensive public Wi-Fi network which has over 220,000 access points across Japan. In Japan, Wi-Fi is recognized as an important infrastructure that is one of the fundamental broadband networks,  such as optical fiber internet access and LTE internet access. It has also evolved to become an essential social foundation providing not only LTE traffic offload, but also providing social and business values to make difference for enterprise and public sectors not only with high quality WiFi but also with value-added services over WiFi.  Japan is one of the top four global LTE markets, with over 90 million LTE subscriptions*. LTE traffic has been rapidly growing, and further rapid growth is expected as more smart Internet of Things (IoT) devices connect to networks. NTTBP aims to offload LTE traffic to its high performance Wi-Fi networks to optimise LTE performance, and enhance subscribers’ mobile internet experience with fast Wi-Fi access. Clavister will deliver its security solution to ensure that NTTBP stays in control of its network, and to support the potential for new value-added services and revenue streams.  The Clavister solution is highly scalable, and can be integrated quickly and effectively with the NTTBP network infrastructure.  The security deployment will also support NTTBP’s network plans ahead of the 2020 Olympics in Tokyo. “Due to the increasing LTE traffic load and the demand for efficient, secure, high quality Wi-Fi Services, it is important to work with a security supplier that can deliver a high-performance and scalable security solution.  We are confident the Clavister solution implemented by MIRAIT will meet not only these demands across our growing network but also something we have seen in the market, which will be profitable service in security issue over free Wi-Fi. Clavister is the fastest company among candidates, that adapts the strategy of NTTBP” said Toshiya Masuzawa, Executive Manager, Senior Vice President, NTTBP. Jim Carlsson, CEO of Clavister, said: “Working with our partner MIRAIT, we are enhancing NTTBP users’ mobile internet experience, giving them the fast Web access, performance and security they expect across the country.  The solution relieves pressure on LTE networks in areas of dense population, while enabling seamless mobile browsing.  It also supports roll-out of targeted, value-added services for subscribers.  The scalability of our solution gives it the capability to secure country-wide Wi-Fi networks, enabling the provision of resources and public services to subscribers and tourists – the possibilities really are endless.” “NTTBP has sole responsibility for the Wi-Fi business as one of the NTT Group companies, whose core business is telecoms and is one of the leading enterprise groups in Japan.  NTT Group views cloud services as its core business for growth, and places great expectations on the Wi-Fi business as one of the key success factors.  MIRAIT is fully aware that NTTBP in accordance with NTT Group companies’ strategy, plans to strengthen security in their Wi-Fi business. Clavister’s solution for operators offers a high level performance and security.” Says Shigeru Yanagisawa, Managing Executive Officer, Head of Solution Business Headquarter MIRAIT. *  Ericsson North East Asia Mobility Report:  https://www.ericsson.com/res/docs/2015/mobility-report/emr-nov-2015-regional-report-north-east-asia.pdf //ENDS About NTTBP (and NTT)  NTT Broadband Platform Inc. (NTTBP) is a group corporation of Nipon Telegraph and Telephone Corp which provides fiber-optic broadband services and mobile broadband services as well as telecommunication services through its group companies, such as  NTT East corp., NTT West corp., NTT Communications, and NTT docomo. NTTBP has 15 years experience in Wi-Fi businesses since July of 2002 in business domains of Wi-Fi businesses, such as Wi-Fi whole-sale for telecommunication carriers, enterprise Wi-Fi provider for transportation, convenience stores, and public sectors, and value-addes services in advertisement, marketing oriented contents management services, and data analytics. It has also provided Wi-Fi in high-density traffic venues such as Convention centers and Sports Studiums with venue-dedicated visitor services including video streaming, 360 degree viewing and 3D AR services. About MIRAIT MIRAIT Corporation (MIRAIT), a leading ICT integrator in Japan, has conducted business creating communication infrastructures for over 70 years as partners of telecommunications carriers. MIRAIT Holdings, its parent company, had net sales of 270 billion yen in the FYE March 2016, growing into the industry's leading groups. The Group conducts business in a wide range of areas including ICT, the environment and energy, based on the creation of communication infrastructure (fixed communication and mobile communication) that is its main business, accounts for about 60% of net sales.  With nationwide business expansion and multi-carrier compatibility, MIRAIT is actively expanding new growing markets, such as network security, cloud solution and other innovative areas. MIRAIT share is listed on 1st Section of Tokyo Stock Exchange and has approximately 24,056 shareholders. For more information about MIRAIT, visit www.mrt.mirait.co.jp/english.

German media group signs agreement with Cxense for personalization offering

Oslo, Norway – 6 December 2016 – Cxense ASA (OSE: CXENSE) today announced that Rhein Main Digital GmbH has signed an agreement with Cxense for the use of its Data Management and Personalization Software.Rhein Main Digital is a subsidiary of Verlagsgruppe Rhein Main, a leading media group publishing 29 daily newspapers in the Hessen and Rheinland-Pfalz regions of Germany, reaching close to 1 million readers. The company is responsible for all group internet activities including publishing content across the various group sites covering newspapers, video news and events. Rhein Main Digital also handles all online marketing for the group, as well as acting as an independent digital agency for external customers.  The company has licensed Cxense Insight, Cxense DMP and Cxense Content. The target is to use online personalization to increase user engagement and drive subscriber conversion.About Cxense:Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide.Customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, Ebay, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, South China Morning Post, AEON, DMM, Rakuten and many more. For more information: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE.'Investor Relations Contact:Jørgen Loeng, Chief Financial OfficerEmail: jorgen.loeng@cxense.comMobile: +47 906 60 062

Mr. Trond Myklebust appointed as new CEO of Viking Supply Ships AB

The Board of Directors of Viking Supply Ships AB has appointed Mr. Trond Myklebust as Chief Executive Officer (CEO). Mr. Myklebust will also act as CEO in Viking Supply Ships A/S, and will take over the responsibilities as CEO in both companies ultimo January. Mr. Myklebust is currently employed as CEO of Fjord Shipping AS. He has extensive experience from the Offshore industry, most notably from his position as Managing Director of Bourbon Norway and ship broker and General Manager within Seabrokers. He has also been Managing Director of Kongsberg Evotec and has a long career as Chief Officer and Master within the Norwegian Coastguard and Remøy/Havila. Mr. Myklebust is a Master Mariner from Aalesund University College. With effect as of the same date, Mr. Bengt A. Rem will be reinstated as Chairman of the Board of Viking Supply Ships AB. Mr. Folke Patriksson will return to his previous position as Deputy Chairman. For further information please contact:   Bengt A. Rem, Interim CEO, tel. +47 94 01 71 71, e-mail bengt.rem@kistefos.no  Morten G. Aggvin, IR & Treasury Director, tel: +47 41 04 71 25, mga@vikingsupply.com. Viking Supply Ships AB is the parent company of a Swedish shipping group with its main office in Gothenburg, Sweden. The Group conducts its business in four segments: Anchor Handling Tug Supply ships (AHTS), Platform Supply Vessels (PSV), Services and Ship Management. The business is focused within offshore and ice-breaking primarily in Arctic and subarctic areas. The Group has approximately 500 employees and its revenue for 2015 amounted to MSEK 1.114. The Company’s series B share is listed at Nasdaq Stockholm, Small Cap segment. www.vikingsupply.com. This information is information that Viking Supply Ships AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on 6 December 2016. 

The leading media house in Malaysia signs agreement with Cxense

Oslo, Norway – 6 December 2016 – Cxense ASA (OSE: CXENSE) today announced that Media Prima Berhad has signed an agreement with Cxense for the use of its Data Management and Personalization Software.Media Prima is Malaysia’s leading fully-integrated media company and one of the top 100 listed companies in the country by revenue. The group has a complete repertoire of media-related businesses including television, print, radio, out-of-home, as well as content and digital media.Media Prima has licensed Cxense Insight, Cxense DMP and Cxense Content. The personalization offering will be used to increase user engagement on Media Prima’s digital sites and applications, to strengthen user loyalty and to build richer user profiles in order to improve editorial planning and increase digital revenue.About Cxense:Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide.Customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, Ebay, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, South China Morning Post, AEON, DMM, Rakuten and many more. For more information: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE.'Investor Relations Contact:Jørgen Loeng, Chief Financial OfficerEmail: jorgen.loeng@cxense.comMobile: +47 906 60 062

Sectra enters the African market with new partnership

“Healthcare in Africa is entering a phase of modernization. This partnership with Tecmed Africa enables Sectra to be part of that transformation and, based on our extensive experience from markets where similar modernization has taken place, help African hospitals to tackle their challenges,” says Dr. Torbjörn Kronander, President and CEO of Sectra. The partnership agreement with Tecmed Africa includes distribution of Sectra’s Enterprise Image Management solutions comprising PACS (Picture Archiving and Communication System) for imaging-intense departments, VNA (Vendor Neutral Archive) and Cross Enterprise Workflow.  “Through this partnership with Sectra, we can now offer our customers solutions with higher availability and better integration possibilities. This will allow our customers to improve collaboration across the clinical pathway, thereby improving patient care,” says Peter Thome, Business Development Manager at Tecmed Africa, Informatics/IT. About Tecmed AfricaTecmed Africa operates in South Africa and has representation in several other countries in the Sub-Saharan region. The company has been in the market for more than 20 years and provides leading medical equipment and solutions to the healthcare sector. It also supplies locally developed solutions for African market, conditions and customer requirements. For more information about Tecmed Africa, http://www.tecmedafrica.com/.

KappAhl bulletin Annual General Meeting 2016

A summary is given below of the resolutions passed, which are all in line with the main resolution proposals made available to the shareholders before the Annual General Meeting. Resolution on adoption of the accounts and discharge from liabilityThe income statement and balance sheet and consolidated income statement and balance sheet were adopted and the meeting discharged the Board of Directors and Chief Executive Officers from liability for the financial year. Resolution regarding dividendThe Annual General Meeting resolved on that a cash dividend of SEK 1.25 per share is distributed for 2015/2016, corresponding to a total of SEK 96,025,475. The remaining profit is carried forward. Record day for the dividend is Thursday 8 December 2016. Expected date of payment via Euroclear is Tuesday 13 December 2015. Determination of fees to the Board of Directors and the AuditorThe meeting resolved that the fee to the Board of Directors and its committees shall be SEK 1,819,000. The resolution means that the Chairman of the Board is awarded SEK 400,000, that each other elected member of the Board is awarded SEK 200,000, that the chairman of the Audit Committee is awarded SEK 160,000 that one other member of the Audit Committee is awarded SEK 100,000, that the chairman of the Remuneration Committee is awarded SEK 35,000 and that one other member of the Remuneration Committee is awarded SEK 12,000. It was resolved that the fee to the accounting firm shall be unchanged in accordance with customary standards and approved invoice. Re-election and election of the Board of DirectorsFour ordinary members of the Board, including Chairman of the Board, were re-elected in accordance with the recommendation of the Nominations Committee. Christian W. Jansson had declined re-election. The Annual General Meeting elected Göran Bille and Cecilia Kocken as new ordinary members of the Board. Consequently, the members of the Board of Directors elected by the Annual General Meeting are Anders Bülow (Chairman), Pia Rudengren, Susanne Holmberg, Kicki Olivensjö, Göran Bille and Cecilia Kocken. Election of accounting firmPwC (PricewaterhouseCoopers AB) was elected new accounting firm, with Eva Carlsvi as the principally responsible auditor. The engagement will run until the next Annual General Meeting. Instructions for the Nominations CommitteeThe Nominations Committee’s proposed instructions and rules of procedure for the Nominations Committee were adopted. The Nominations Committee shall consist of four ordinary members, who shall be appointed by the four largest shareholders as of April 30. The term largest shareholders refers to shareholders registered with Euroclear Sweden AB and grouped by ownership as of April 30. Remuneration policy for company managementThe meeting adopted the Board's proposed remuneration policy for the management team. The policy implies that a bonus of a maximum of 50 per cent of fixed salary can be payable. The remuneration policy is substantially the same as the one adopted by the previous Annual General Meeting. All the resolutions of the Annual General Meeting were passed with the requisite majority. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Unibet Group becomes Kindred Group

The shareholders of Unibet Group plc today voted to change the name of the holding company from Unibet Group plc to Kindred Group plc. The strategic business rationale behind this decision relates to the fact that Unibet Group is a growing and changing company that today has ten consumer facing brands in the portfolio, many of them acquired. Unibet Group has operated with a multi-brand strategy since the acquisition of Maria Casino in 2007, a strategy which is now fully adopted with the Kindred Group brand. “Changing our group name from Unibet Group to Kindred Group marks an historic step for our company, founded almost twenty years ago. We are now in a position to move Kindred Group into the future with enhanced clarity and flexibility, creating better conditions for future growth in a dynamic and changing business environment”, says Anders Ström, Chairman of the Board of Directors of Unibet Group. “As Kindred we can create a greater distinction between our consumer facing brands and the group brand, providing us with the necessary strategic flexibility to ensure we remain at the very forefront of our industry. As a group we have played an important part in driving the industry forward, and we intend to continue to do so in the future”, says Henrik Tjärnström, CEO of Unibet Group. The chosen name is based on an extensive analysis of the Group culture and identity. If you look up the word kindred in the dictionary, you will find that it refers to a relationship between people with similar beliefs, values and attitudes. The Unibet Group are proud of their strong culture and great people, and this proposed name truly describes the people of the Group.

EQT Infrastructure to acquire Delta Comfort

· EQT Infrastructure to acquire Delta Comfort, the leading telecom infrastructure company and supplier of energy in the Dutch province of Zeeland  · EQT Infrastructure to support Delta Comfort in further strengthening its position as the preferred telecommunication infrastructure access provider for the Zeeland community  · New Board of Directors will be composed of a highly relevant set of industry leaders from the telecom and energy sectors to support management of Delta Comfort The EQT Infrastructure investment strategy (“EQT Infrastructure”) has signed definitive transaction documentation to acquire Delta Comfort B.V. (”Delta Comfort” or “the Company”) from Delta N.V., the municipality and province owned integrated utility company of the Dutch province of Zeeland. The purchase price amounts to EUR 488 million. Delta Comfort is the leading telecom infrastructure owner and operator, provider of multimedia services (broadband, TV, telephony) and supplier of energy, serving over 140,000 households and businesses mainly in the Dutch province of Zeeland. Delta Comfort’s hybrid fiber-coaxial (HFC) network of over 6,000km passes 192,000 homes, which corresponds to ~90% of the total number of homes in Zeeland. Delta Comfort employs approximately 370 people and generated sales of EUR 214 million in 2015. Going forward, the strategy is to further develop the Company’s unique multi-utility approach, invest in its network to provide the most advanced solutions to residential and business clients and therefore strengthen its position as the preferred telecommunication infrastructure access provider in Zeeland. The growth of the Company will be supported by an industrial board of directors who will have significant telecom and energy expertise. Harko Buringh, CEO of Delta Comfort, said: “We are excited to join EQT Infrastructure, one of the world’s most respected infrastructure funds, with a strong heritage in the telecom sector. They have a growth focused strategy, a responsible and hands-on ownership approach and will provide us with access to an extensive network of industry specialists.” Matthias Fackler, Partner at EQT Partners and Investment Advisor to EQT Infrastructure, said: “We are impressed with Delta Comfort’s superior network infrastructure, unique multi-utility product offering and leading position in Zeeland. We are very enthusiastic about the future of Delta Comfort and the opportunities the EQT industrial investment approach will bring to the Company’s next development phase.” The transaction is subject to customary conditions, such as completion of a works council consultation procedure, approval of the shareholders of Delta N.V. and the Autoriteit Consument & Markt (ACM). It is expected to close in the first quarter of 2017. ING acted as sole financial advisor and Clifford Chance as legal advisor to EQT Infrastructure. Contacts:Matthias Fackler, Partner at EQT Partners, Investment Advisor to EQT Infrastructure, +49 89 2554 99520Kerstin Danasten, EQT Press Officer, +46 8 506 55 334 About EQTEQT is a leading alternative investments firm with approximately EUR 31 billion in raised capital across 21 funds. EQT Funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. EQT Funds current investments in the Netherlands include TransIP, Bureau van Dijk and 3D Hubs More info: www.eqtpartners.com About Delta ComfortDelta Comfort offers multimedia and energy solutions to residential and business clients in the province of Zeeland. Delta Comfort owns and operates a hybrid fiber-coaxial (HFC) network of 3,400km of fiber and 3,000km of coaxial cables, which passes 192,000 households in the region. Delta Comfort employs approximately 370 people and generated sales of EUR 214 million in 2015. It is headquartered in Middelburg, the capital of Zeeland, Netherlands. More info: www.delta.nl/en/about-delta

OrganoClick - one of Sweden's fastest growing technology company!

Affärsvärlden, Sweden’s leading business magazine, has recently published an article on this year's "Sweden Technology Fast 50", Deloitte's independent ranking of the fastest growing technology companies. The ranking show continued strong sales growth in the Swedish technology industry. Among the 10 fastest technology companies are among others Fingerprint Cards, iZettle and Q-channel. OrganoClick meets all the formal requirements for the list and would be placed on a 6th place, with its growth rate of 2828%, but was not on the list because the activity code (SIC code) OrganoClick has was not included in the Deloitte survey. The article in Affärsvärlden told of the ranking of the Fast50 companies. The ranking is based on Sweden's 50 fastest growing technology companies, in terms of sales performance during the past four years. Deloitte does the rankings based on a number of formal criteria that companies must meet (see below). Selecting technology companies from going through the companies operating codes from the Swedish Tax Agency. Unfortunately, the operating code that OrganoClick® is registered under, was not included this year but Deloitte confirms in writing that OrganoClick® meets all the formal requirements for the list. - At OrganoClick we are incredibly proud that we have grown so quickly but clearly we are a bit disappointed that we were not published on the Fast50 official list. A potential 6th place in the competition with Sweden's fastest growing IT companies is even better than we have hoped. The most important of all, however, is that all our growth contributes to a better environment. In coming years, we accelerate even more - because we see great potential for green chemistry and renewable materials, says Mårten Hellberg, CEO of OrganoClick AB. Fast50 – The entire list: http://www.fast50.se/ Deloitte’s own press release: https://www2.deloitte.com/se/sv/footerlinks/pressreleasespage/deloitte-sweden-technology-fast-50-20151.html ......................................................................................... For more information, please contact: Mårten Hellberg, CEO 0707 - 16 48 90, marten.hellberg@organoclick.com ......................................................................................... About OrganoClick OrganoClick AB (publ) is a public Swedish cleantech company listed on Nasdaq First North. The company develops, produces and markets functional materials based on environmentally friendly fiber chemistry. Examples of products that are marketed by OrganoClick are the water repellent fabric treatment OrganoTex®, the flame and rot-resistant timber OrganoWood® and biocomposite materials. OrganoClick was founded in 2006 as a commercial spin-off company based on research performed at Stockholm University and the Swedish University of Agricultural Sciences within environmentally friendly fiber chemistry. OrganoClick has won a number of prizes, such as "Sweden's Most Promising Start -up" and "Sweden's Best Environmental Innovation", and has also received a number of awards, such as the WWF "Climate Solver" award and has also appeared for two years on the Affärsvärldens and NyTekniks list of Sweden's top 33 hottest technology companies. OrganoClick has its head office, production and R&D located in Täby, north of Stockholm. OrganoClick's Certified Adviser on Nasdaq First North is Erik Penser Bank.  The information in this press release contains information that OrganoClick AB (publ) is obliged to release according to the EU's market regulation law number 596/2014. The information was published, of the contact person above, 6th December 2016 at 15:30. 

Nordic Nanovector launches a private placement of new shares

THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 6 December 2016Nordic Nanovector ASA (OSE: NANO) (“Nordic Nanovector” or the “Company”), announces the launch of an undocumented private placement of up to 4,374,244 new shares, representing approximately 10% of the outstanding share capital of the company (the “Offering”). DNB Markets, Jefferies International Limited and ABG Sundal Collier are acting as joint bookrunners (the “Joint Bookrunners”) in connection with the Offering. Nordic Nanovector intends to use the net proceeds of the Offering: To fund a Phase 2 combination study of Betalutin® and Rituximab CD20 To fund a Phase 1 study and GMP manufacturing for 177Lu-conjugated chimeric antibody (anti-CD37 ARC) Develop new proprietary antibody production technology Accelerate pipeline of pre-clinical assets to clinical trials Prepare for commercial launch of Betalutin® General corporate purposes The subscription price and the number of shares to be issued in the Offering will be determined through an accelerated bookbuilding process.The bookbuilding period for the Offering opens today at 16:30 CET and closes 7 December 2016 at 08:00 CET. The Company and the Joint Bookrunners may, however, at any time resolve to close or extend the bookbuilding period at their sole discretion and on short notice. The minimum subscription and allocation amount in the Offering will be the NOK equivalent of EUR 100,000, provided that the Company may, at its sole discretion, allocate an amount below EUR 100,000 to the extent applicable exemptions from the prospectus requirement pursuant to applicable regulations, including the Norwegian Securities Trading Act and ancillary regulations, are available. Allocation of the new shares will be determined at the end of the bookbuilding process, and final allocation will be made by the Company's Board of Directors at its sole discretion, following advice from the Joint Bookrunners. The shares to be issued in connection with the Offering will be issued based on the board authorisation granted at the Company's annual general meeting on 19 May 2016. In line with the shareholders’ approval, pre-emption rights of the existing shareholders are excluded. The Offering will be directed towards Norwegian and international investors, in each case subject to and in compliance with applicable exemptions from relevant prospectus or registration requirements. Notification of allotment and payment instructions will be sent to the applicants on or about 7 December 2016 through a notification to be issued by the Joint Bookrunners.Offer shares will be settled with existing and unencumbered shares in the Company that are already listed on the Oslo Stock Exchange, pursuant to a share lending agreement between DNB Markets (on behalf of the Joint Bookrunners) and HealthCap VI L.P., in order to facilitate delivery of listed shares to investors on a delivery versus payment basis. The offer shares delivered to the subscribers will thus be tradable from allocation. The Joint Bookrunners will settle the share loan with new shares in the Company to be issued by the Board of Directors pursuant to the aforementioned authorisation granted at the annual general meeting held on 19 May 2016. The Company, its board members, executive management and major shareholder have all agreed with the Joint Bookrunners to a lock-up on future share issuances and existing shareholdings, as applicable, for a period of 180 days from the closing date, subject to customary and de minimis exceptions. The Company will announce the final number of offer shares placed and the final subscription price in the Offering in a stock exchange announcement expected to be published before opening of trading on the Oslo Stock Exchange tomorrow, 7 December 2016. The Offering is subject to final approval by the Company’s Board of Directors. For further information, please contact:For Nordic NanovectorIR enquiries:Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab, conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its pipeline of innovative targeted immunoconjugate therapies for multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Important NoticesThis document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.This document is not for publication or distribution in the United States of America, Canada, Australia or Japan and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States of America or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended (the “Securities Act”)) or to publications with a general circulation in the United States of America. This document is not an offer for sale of securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act, or the laws of any state, and may not be offered or sold in the United States of America absent registration under or an exemption from registration under Securities Act. Nordic Nanovector does not intend to register any part of the offering in the United States, There will be no public offering of the securities in the United States of America. Any public offering in the United States would be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.Any offer of securities to the public that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an “EEA Member State”) that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.Investing in securities involves certain risks. You should read the Risk Factors contained in the prospectus dated 10 March 2015 (available at http://www.nordicnanovector.com/investor-relations/reports-and-presentations/prospectus), but they should be read in light of any new or additional information contained in any further publicly available information since the date of the prospectus.This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Nordic Nanovector and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Nordic Nanovector assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Moberg Pharma considers an acquisition of a brand from Prestige Brands and evaluates the preconditions for carrying out a directed new shares issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, NEW ZEELAND, SOUTH AFRICA, HONG KONG OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL Summary of the considered acquisition and its overall effects•    Moberg Pharma has an exclusive option to acquire DermoPlast® from Prestige Brands (“Prestige”). Moberg Pharma considers to, on or around December 7th, 2016, enter into a binding acquisition agreement with Prestige to acquire DermoPlast® for a purchase price of USD 47.6M plus stock value. A final decision on such acquisition and the entering into an acquisition agreement is dependent on the Company first being able to secure financing. A potential transaction is expected to be completed during December 2016.•    Based on Moberg Pharma’s cost structure and accounting principles, the purchase price corresponds to approximately 8.9 times the estimated EBITDA for DermoPlast® for the period 1 October 2015–31 September 2016.•    DermoPlast® will be sold through Moberg Pharma’s established sales channels in the U.S., primarily in chain drugstores such as CVS, Walgreens and Rite Aid and in mass retailers, such as Walmart and Target and directly to hospitals.•    DermoPlast® is an anesthetic spray used externally for relief of pain and itching from skin chaps and skin injuries. The hospital sales are primarily focused on women, for usage on skin chaps and vaginal injuries and surgery in connection with or after childbirth.•    DermoPlast® will be included among Moberg Pharma’s strategic brands, and is expected to be the Company’s second largest product.•    At a completed acquisition of DermoPlast® it is expected that the brand, immediately following completion, will contribute positively to both the Company’s profit and cash flow per share, also considering financing costs.•    Moberg Pharma intends to partially finance the acquisition through a directed share issue of up to 2,843,504 shares through a so-called "accelerated book-building", and has mandated Carnegie Investment Bank to assess the preconditions therefor. “The acquisition of DermoPlast® is in line with our strategy and leverages our existing infrastructure and sales channels in the U.S. in an excellent way. The acquisition brings increased economies of scale and complements our portfolio with a strong and profitable dermatology brand. We are very pleased with this transaction, which is expected to contribute positively to both our sales and profitability and thereby to our long term financial target to deliver profitable growth and an EBITDA margin of 25 per cent”, says Peter Wolpert, CEO of Moberg Pharma. Background to the acquisition of DermoPlast® A central part of Moberg Pharma’s strategy is to acquire Over-the-Counter brands that complement the Company’s existing portfolio. Moberg Pharma is continuously evaluating possible acquisition of such complementary brands. One such possible acquisition is the brand DermoPlast® from Prestige. In June 2016, Moberg Pharma announced its acquisition of the three well-established U.S. Over-The-Counter brands New Skin®, Fiber Choice® and PediaCare® (under divestment) from Prestige. Subsequently, Moberg Pharma has secured an exclusive right to also acquire DermoPlast® from Prestige for an USD 1.25M option fee. The option provides Moberg Pharma with a one-time right to perform an evaluation of DermoPlast® on exclusive basis and following which evaluation Moberg Pharma, at its own discretion, can decide to complete an acquisition of DermoPlast® at an agreed multiple of the contribution margin of the product. Moberg Pharma has performed such an evaluation of DermoPlast® and on the basis thereof Moberg Pharma considers to complete the acquisition. A final decision is however dependent on that the Company has secured financing before any binding acquisition agreement is entered into. In addition to a directed issue of ordinary shares, Moberg Pharma intends to finance the contemplated acquisition of DermoPlast® by available cash resources and a tap issue to Moberg Pharma’s outstanding bond loan (ISIN: SE0007953989) of approximately SEK 215M. In the event of an acquisition of DermoPlast® the product will be included among Moberg Pharma’s strategic brands, and is expected to be the Company’s second largest product. DermoPlast® in shortDermoPlast® is an anesthetic spray used externally for relief of pain and itching from skin chaps and skin injuries. DermoPlast® will be sold through Moberg Pharma’s established sales channels in the U.S., via chain drugstores such as CVS, Walgreens and Rite Aid and in mass retailers such as Walmart and Target and directly to hospitals. The hospital sales is primarily focused on women, for usage on skin chaps and vaginal injuries and surgery in connection with or after childbirth. Prestige does not report DermoPlast® separately. However, based on information from Prestige’s public financial statements and Prestige’s internal accounting and reporting system, Moberg Pharma has made certain appraisals of the financial effects of an acquisition of DermoPlast®. These estimates are uncertain and have not been audited and should thus be treated with caution. Nonetheless, based on available information, the Company estimates that DermoPlast® during the period 1 October 2015-30 September 2016, and with application of IFRS and the Company’s accounting principles, experienced net sales of USD 12.0M and an EBITDA of USD 5.4M, equivalent to a EBITDA margin of approximately 45 per cent. Furthermore, the Company estimates that DermoPlast® has during recent years, with application of IFRS and the Company’s accounting principles, experienced increased net sales as follows: ·  2016/2015: USD 12.0M (12 months until 30 September 2016) ·  2015: USD 10.4M ·  2014: USD 9.8M ·  2013: USD 9.8M The EBITDA margin of the product has been stable during the period 2013-2016. In the event of an acquisition of DermoPlast®, the purchase price will amount to USD 47.6M plus stock value and with deduction of the already paid USD 1,25M option fee. The purchase price is intended to be financed partially by a tap issue to the Company’s outstanding bond loan, which bears annual interest equivalent to STIBOR 3M plus 6.00 per cent, of approximately SEK 215M and partially by available cash resources and also through the net proceeds from a directed new shares issue. Assuming completion of these transactions, the Company’s net debt is estimated to increase by approximately SEK 300M if the acquisition of DermoPlast® is carried out. A potential acquisition of DermoPlast® is expected to be completed during December 2016 and DermoPlast® will be consolidated in Moberg Pharma’s accounts thereafter. A potential acquisition of DermoPlast® is expected to, immediately following completion, contribute positively to both the Company’s profit and cash flow per share, also considering financing costs and additional shares. Engagement of Carnegie to evaluate the preconditions for a private placementMoberg Pharma intends to partially finance the contemplated acquisition of DermoPlast® through a direct issue of up to 2,843,504 shares. Therefore Moberg Pharma has, based on the authorization to issue shares granted by the Company’s annual general meeting on 18 May 2016, mandated Carnegie Investment Bank to assess the preconditions for a private placement of up to 2,843,504 shares, through a so-called “accelerated book-building” procedure. In addition hereto, the Company has mandated Carnegie Investment Bank and Swedbank to assess the preconditions for a tap issue to the Company’s outstanding bond loan of approximately SEK 215M. AdvisorsCarnegie Investment Bank has been engaged as financial advisor regarding the directed share issue and Carnegie Investment Bank and Swedbank have been engaged as financial advisors regarding the tap issue to the Company’s outstanding bond loan. Hansen Law has been engaged as legal advisor regarding the potential acquisition of DermoPlast® and Gernandt & Danielsson as legal advisor regarding the financing. About this information              This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 17.30 p.m. (CET) on December 6th, 2016. Disclaimer/NoticeThis communication is not an offer of securities for sale in the United States or any other jurisdiction. Any securities referred to in this communication may not be offered or sold in the United States or any other jurisdiction absent registration under applicable securities laws or an exemption from registration.

Vattenfall enters the Danish consumer market

Vattenfall has a strategy to enter new markets through small and innovative sales companies with an existing customer base. The acquisition of Vindstød.dk and the entry into the Danish consumer sales market is a part of this. “The demand in the market makes it a natural step for us to move from being a wind power developer and operator to also start providing Danish customers with 100% renewable energy. Vindstød.dk is an innovative, successful and fast-growing company which has pioneered the Danish consumer market”, says Martijn Hagens, Head of Customers & Solutions, Vattenfall. Following three successful bids for major Danish offshore wind farms, Vattenfall is now also able to offer wind power to private customers. This is in line with Vattenfall´s strategy to be leading in sustainable energy production and consumption. “The acquisition in Denmark provides us with an attractive customer base, a strong IT-platform and an efficient organisation. We will now speed up the Vindstød.dk success-story even further, building on the 100% local wind power promise and scalable setup. We aim to grow the business significantly”, says Martijn Hagens. Vattenfall has a strong position in Denmark as the biggest onshore wind developer and operator and will soon be the biggest in offshore as well. Offering customers sustainable energy supply from a company such as Vindstød.dk is an attractive complement to the existing business in Denmark. “The Danish consumer market has large growth potential. The acquisition of Vindstød.dk is a start, and we want to open up a dialogue with similar companies to discuss their business with us”, says Martijn Hagens. Vattenfall and Vindstød.dk have agreed not to disclose the financial details of the transaction. Facts:Vindstød.dk was started in 2012 by Morten Nissen Nielsen and supplies 100% wind power that is bought from Danish wind power producers. The founder of Vindstød.dk, Morten Nissen Nielsen, will stay on as Managing Director. More information:Wind power in Vattenfall (https://corporate.vattenfall.com/about-energy/renewable-energy-sources/wind_power/wind-power-at-vattenfall/)Vindstød.dk (https://www.vindstoed.dk/) For further information, please contact:Heidi Stenström, Press Officer, +46 70 611 81 92,   (heidi.stenstrom@vattenfall.com)heidi.stenstrom@vattenfall.com (heidi.stenstrom@vattenfall.comVattenfall’s)Vattenfall’s Press Office, telephone: +46 8 739 5010, press@vattenfall.com

Clas Ohlson six-month report 2016/17

Six months · Sales increased by 3% to 3,720 MSEK (3,616), 4% in local currencies · Operating profit amounted to 202 MSEK (250) · Profit after tax amounted to 154 MSEK (192) · Earnings per share amounted to 2.44 SEK (3.03) · Cash flow from operating activities amounted to 44 MSEK (322) Events after the end of the reporting period · November sales increased by 12% to 908 MSEK (809), 9% in local currencies · The store portfolio was extended by a second franchise store in Dubai, a third store in Hamburg, and a further two stores in Finland The 2016/17 financial year comprises the period from 1 May 2016 to 30 April 2017. CEO’s commentsHealthy underlying trend, but negative currency effect During our second quarter, we continued to develop our business in the right direction and took new steps in Germany with online shopping and additional stores. However, results were strongly impacted by negative effects of currency hedging in NOK. We are continuing to grow and sales increased by 6 per cent to 1,957 MSEK. We work continuously to strengthen our offering and have taken further key steps this quarter. These include the launch of our rent service, which we are now testing in a number of selected stores, and the opening of our first Clas Ohlson Compact Store at Hornstull in Stockholm, a new store format for enhanced accessibility. In the autumn, we also completed the first stage of our establishment in the German market, with online shopping and three stores in prime locations in Hamburg. During the autumn, we also established a further franchise store in Dubai. Stronger Norwegian krona has major consequences Despite a healthy underlying trend, we have reported lower results mainly due to negative effects of currency hedging in NOK. In a short time, the NOK has strengthened significantly against the SEK, with the effect that our currency forwards and hedges through inventory delays have had a significant impact on results. Compared with the preceding year, when the currency trend was the opposite, currency hedging had a substantial negative impact on profit. However, I want to emphasise that a strengthened NOK is essentially very positive for Clas Ohlson since nearly 40 per cent of our sales are in NOK. Good start to Christmas trading Ahead of Christmas shopping, we have filled our sales channels with lots of great offers, both for Christmas celebrations and Christmas gifts. Today, we are reporting a great start to Christmas trading, with sales in November up 12 per cent to 908 MSEK. For me personally, this report is my last, since I have chosen to leave my position at the end of the year. I am incredibly proud of all my fantastic colleagues and what we have achieved together in the nearly ten years I have been with Clas Ohlson. I look forward to following the company’s continued development and expansion, albeit from more of a distance. Klas Balkow, President and CEO of Clas Ohlson AB Press and analyst conference The six-month report will be presented on 7 December at 8:30 a.m. by teleconference or audio broadcast. The presentation can also be followed on about.clasohlson.com This is information that Clas Ohlson AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:00 am CET on 7 December 2016.

Senior management changes at Handelsbanken

Rolf Marquardt has been appointed CFO of Handelsbanken. He has been a member of the Bank’s Senior Management since 2015, and since September this year he has been Acting CFO.  Pål Bergström has been appointed Head of Handelsbanken’s Group Compliance. He has been a member of the Bank’s Senior Management since 2016, and since September this year he has been Acting Head of Group Compliance.  Stina Petersson has been appointed Head of Group Human Resources at Handelsbanken. She will also be a member of the Group’s Senior Management. Stina Petersson is currently responsible for management succession planning and leadership development within Group Human Resources.  All the above take up their new positions on 7 December 2016.  Stina Petersson succeeds Anders Öhman, who will reach his contractual age of retirement in the first half of 2017. He is therefore leaving Senior Management on 7 December 2016. During the period until his retirement, he will be working in an advisory capacity at Group Human Resources.  For further information, please contact:  Anders Bouvin, President and Group Chief Executive, +46 8–22 92 20Johan Lagerström, Chief Communications Officer,+46 8–701 13 95,+ 46 70–265 80 14Johan Wallqvist, Head of Group Media Relations, +46 8–701 80 47,+46 72–206 34 50 This information is of the type that Handelsbanken is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication through the agency of the contact person set out above, at 8.00 CET on 7 December 2016.For more information about Handelsbanken, see: www.handelsbanken.com (http://media.ne.cision.com/l/fbpxcdcv/www.handelsbanken.se/)

Moberg Pharma issues shares, secures acquisition financing and acquires DermoPlast

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, NEW ZEELAND, SOUTH AFRICA, HONG KONG OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL  Moberg Pharma has, based on the authorization granted by Moberg Pharma’s Annual General Meeting on May 18th, 2016, carried out a private placement through a direct share issue of 2,843,504 shares, each at a total subscription price of SEK 52 per share (the “Issue”). The subscription price in the Issue has been determined through a so-called “accelerated book-building” procedure led by Carnegie Investment Bank. Subscribers in the Issue are a wide range of Swedish and international institutional investors. Through the Issue, which was announced on December 6th, 2016, Moberg Pharma will receive proceeds amounting to approximately SEK 148M. The company also intends to conduct a tap issue in the amount of SEK 215M under its outstanding bond loan and has received binding commitments for the same amount. As communicated, the company intends to use proceeds from the Issue, the bond issue and cash at hand to finance the acquisition of DermoPlast®.  DermoPlast® is an anesthetic spray used externally for relief of pain and itching from skin chaps and skin injuries. DermoPlast® will be sold through Moberg Pharma’s established sales channels in the U.S., via chain drugstores such as CVS, Walgreens and Rite Aid and in mass retailers such as Walmart and Target and directly to hospitals. The hospital sales are primarily focused on women, for usage on skin chaps and vaginal injuries and surgery in connection with or after childbirth.   Based on available information, the Company estimates that DermoPlast® during the period October 1st, 2015 - September 30th, 2016, and with application of IFRS and the Company’s accounting principles, experienced net sales of USD 12.0M and an EBITDA of USD 5.4M, equivalent to a EBITDA margin of approximately 45 per cent. The purchase price corresponds to approximately 8.9 times the estimated EBITDA for DermoPlast® for the equivalent period.   DermoPlast® will be included among Moberg Pharma’s strategic brands, and is expected to be the company’s second largest product. At a completed acquisition of DermoPlast® it is expected that the brand, immediately following completion, will contribute positively to both the Moberg Pharma’s profit and cash flow per share, also considering financing costs. For further information, please see the company’s press release dated December 6th, 2016.  ”I am proud to announce the acquisition of DermoPlast®. After thorough evaluation and diligence I am very pleased that we have now secured financing to be able to complete this important acquisition for Moberg Pharma. The transaction is expected to contribute positively to our sales and profitability and contribute to our long-term financial target to deliver profitable growth and an EBITDA-margin of 25 percent”, says Peter Wolpert, CEO of Moberg Pharma  "The Board of Directors of Moberg Pharma is very pleased with the acquisition of DermoPlast®. Through the acquisition, the company strengthens its portfolio of strategic brands – DermoPlast® fits perfectly into the company's focus on topical products. We can also fully utilize the existing organization and sales channels in the U.S. After the acquisitions, the company now has three major strategic brands – Kerasal Nail®, DermoPlast® and New Skin® – which increases the diversification and thus strengthens the company. The focus over the coming year is to successfully integrate acquisitions and to strengthen the positioning of our portfolio and to continue to create value through the advancement of our development pipeline." says Thomas Eklund, chairman of Moberg Pharma.  The subscription price of SEK 52 for the new shares implies a discount of approximately 8 per cent based on the closing price of Moberg Pharma’s shares on Nasdaq Stockholm on December 6th, 2016. The subscription price for the shares is based on the accelerated book building procedure on December 6th, 2016 and Moberg Pharma has thereby ensured that the subscription price corresponds to fair market standards. The Issue entails a dilution of approximately 16.6 per cent in relation to the number of existing shares in the Company through an increase in the number of outstanding shares to 17,132,692 shares. The reasons for the derogation from the shareholders’ preferential rights are that it has been considered possible to through the Issue raise capital, in connection with the acquisition of DermoPlast®, to more preferential conditions, in shorter time and to a lower cost than if the shares were offered to current shareholders through a rights issue.  In order to facilitate the delivery of shares to the investors in the Issue, Östersjöstiftelsen will lend shares to Carnegie Investment Bank. In connection with admission for trading of the shares which will be redelivered to Östersjöstiftelsen, Moberg Pharma will publish a listing prospectus.  Advisors Carnegie Investment Bank has been engaged as financial advisor regarding the Issue and Carnegie Investment Bank and Swedbank have been engaged as financial advisors regarding the tap issue to the Company’s outstanding bond loan. Hansen Law has been engaged as legal advisor regarding the acquisition of DermoPlast® and Gernandt & Danielsson as legal advisor regarding the financing.  About this information               This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 08.00 a.m. (CET) on December 7th, 2016.  Disclaimer/NoticeThis communication is not an offer of securities for sale in the United States or any other jurisdiction. Any securities referred to in this communication may not be offered or sold in the United States or any other jurisdiction absent registration under applicable securities laws or an exemption from registration.

Nordic Nanovector – Private placement successfully completed

Oslo, Norway, 7 December 2016 Reference is made to the stock exchange release from Nordic Nanovector ASA (OSE: NANO) (“Nordic Nanovector” or the “Company”), published 6 December 2016 regarding the contemplated undocumented private placement of new shares in the Company. The Company announces today that it has raised NOK 498,663,816 in gross proceeds through a private placement of 4,374,244 new shares (the "Private Placement"). The Private Placement was completed at a subscription price of NOK 114 per share, which was determined through an accelerated book-building process. DNB Markets, Jefferies International Limited and ABG Sundal Collier acted as joint bookrunners (the “Joint Bookrunners”) in connection with the Private Placement, which took place after close of trading yesterday. The Private Placement, which was oversubscribed, attracted strong interest from both existing shareholders and new institutional investors. Nordic Nanovector intends to use the net proceeds of the Private Placement: ·   To fund a Phase 2 combination study of Betalutin® and Rituximab CD20 ·   To fund a Phase 1 study and GMP manufacturing for 177Lu-conjugated chimeric antibody (anti-CD37 ARC) ·   Develop new proprietary antibody production technology ·   Accelerate pipeline of pre-clinical assets to clinical trials ·   Prepare for commercial launch of Betalutin® ·   General corporate purposes The Private Placement and the issuance of the new shares was resolved by the Company’s Board of Directors (the “Board”) at a board meeting held on 6 December 2016, based on the authorisation granted to the Board at the Company's annual general meeting on 19 May 2016. Notification of allotment in the Private Placement and payment instructions will be sent to the applicants today through a notification from the Joint Bookrunners. The new shares will be settled delivery versus payment on 9 December 2016 (regular T+2 settlement), by delivery of existing and unencumbered shares in the Company that are already listed on the Oslo Stock Exchange pursuant to a share lending agreement between DNB Markets (on behalf of the Joint Bookrunners) and HealthCap VI L.P. The new shares delivered to the subscribers will thus be tradable from allocation. Following registration of the new share capital pertaining to the Private Placement in the Norwegian Register of Business Enterprises, expected to take place on or about 13 December 2016, the Company will have an issued share capital of NOK 9,794,924, divided into 48,974,618 shares, each with a par value of NOK 0.20. The Board has assessed the Private Placement in light of the equal treatment requirement, balanced the considerations that speak for and against carrying out the Private Placement and concluded that the waiver of the preferential rights inherent in a private placement was considered necessary in the interest of time and successful completion in the common interest of the Company and its shareholders. The Company’s latest investor presentation is available at: www.nordicnanovector.com/investor-relations/reports-and-presentations/2016-2 For further information, please contact: For Nordic Nanovector IR enquiries: Luigi Costa, Chief Executive Officer Cell: +41 79 124 8601 Tone Kvåle, Chief Financial Officer Cell: +47 91 51 95 76 Email: ir@nordicnanovector.com Media enquiries: Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 282 2948/+44 207 282 2949 Email: nordicnanovector@citigatedr.co.uk  About Nordic Nanovector: Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab, conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its pipeline of innovative targeted immunoconjugate therapies for multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com  This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Important Notices  This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. This document is not for publication or distribution in the United States of America, Canada, Australia or Japan and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States of America or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended (the “Securities Act”)) or to publications with a general circulation in the United States of America. This document is not an offer for sale of securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act, or the laws of any state, and may not be offered or sold in the United States of America absent registration under or an exemption from registration under Securities Act. Nordic Nanovector does not intend to register any part of the offering in the United States, There will be no public offering of the securities in the United States of America. Any public offering in the United States would be made by means of a prospectus containing detailed information about the company and management, as well as financial statements. The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an “EEA Member State”) that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive. Investing in securities involves certain risks. You should read the Risk Factors contained in the prospectus dated 10 March 2015 (available at http://www.nordicnanovector.com/investor-relations/reports-and-presentations/prospectus), but they should be read in light of any new or additional information contained in any further publicly available information since the date of the prospectus. This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Nordic Nanovector and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Nordic Nanovector assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Lemminkäinen decreases the amount of its revolving credit facility

LEMMINKÄINEN CORPORATION  STOCK EXCHANGE RELEASE  7 DECEMBER 2016  AT 9:00 A.M. LEMMINKÄINEN DECREASES THE AMOUNT OF ITS REVOLVING CREDIT FACILITY In March 2016, Lemminkäinen agreed on a EUR 260 million revolving credit facility of which EUR 75 million was available when agreed conditions are met. Lemminkäinen has evaluated its capital structure and come to the conclusion that the EUR 75 million part of the revolving credit facility is no longer needed. The company has cancelled this part of the revolving credit facility on 7 December 2016. The company’s remaining available EUR 185 million committed revolving credit facility is currently undrawn. The revolving credit facility will mature during the first quarter in 2018. Lemminkäinen announced the amended terms of its financial agreement on 23 March 2016. LEMMINKÄINEN CORPORATIONCorporate Communications ADDITIONAL INFORMATION:Ilkka Salonen, CFOTel. +358 2071 53304ilkka.salonen@lemminkainen.com DISTRIBUTION:Nasdaq Helsinki LtdKey mediawww.lemminkainen.com Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and 4,800 professionals we employ, we build a sustainable society. In 2015, our net sales were EUR 1.9 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com

YIT to sell an apartment building project to a private cooperative in Prague, the Czech Republic

YIT has sold an apartment building project to a private cooperative in Prague. The sold apartments are a part of the second phase of Suomi Hloubětín project. The agreement comprises 90 apartments with low energy consumption in three buildings. The total value of the agreement is approximately EUR 10 million. Construction of the project will start at the last quarter of 2016 and it will be completed in summer 2018. Cooperative housing has a long tradition in the Czech Republic. The cooperative buys the building and arranges for the financing of the project. A consumer may join the cooperative by paying a membership fee which entitles him or her to an apartment. By selling the project to co-operative YIT is able to speed up the development of the large area project to improve capital efficiency. YIT has sold a project to the same private cooperative in 2015. For further information, please contact: Hanna Jaakkola, Vice President, Investor Relations, YIT Corporation, tel. +358 40 5666 070, hanna.jaakkola@yit.fi  Tom Sandvik, Head of the Baltic countries and Central Eastern Europe business division, tel. +358 400 617 807, tom.sandvik@yit.fi YIT CORPORATION Hanna Jaakkola Vice President, Investor Relations Distribution: NASDAQ Helsinki, major media, www.yitgroup.com YIT creates better living environment by developing and constructing housing, business premises, infrastructure and entire areas. Our vision is to bring more life in sustainable cities. We want to focus on caring for customer, visionary urban development, passionate execution and inspiring leadership. Our growth engine is urban development involving partners. Our operating area covers Finland, Russia, the Baltic countries, the Czech Republic, Slovakia and Poland. In 2015, our revenue amounted to nearly EUR 1.7 billion, and we employ about 5,300 employees. Our share is listed on Nasdaq Helsinki. www.yitgroup.com

Nomination Committee and date for 2017 AGM of Sectra AB

Sectra has appointed a Nomination Committee comprising four members, one of whom is the Chairman of the Board and three of whom represent the largest shareholders in the company based on the number of votes. The Nomination Committee was formed based on known shareholdings in the company on October 31, 2016 and comprises the following members: ·  Carl-Erik Ridderstråle (Chairman of the Board) ·  Torbjörn Kronander (largest shareholder and CEO) ·  Jan-Olof Brüer (second-largest shareholder and Board member) ·  Jan Särlvik (representing Nordea, the fourth-largest shareholder) Jan-Olof Brüer, who is the company’s second-largest shareholder in terms of votes, has been appointed Chairman of the Nomination Committee. Torbjörn Kronander, the company’s largest shareholder in terms of votes, decided to abstain from the chairmanship due to his role as CEO and President of Sectra AB. The Nomination Committee’s proposals will be presented in the notice of the 2017 AGM and be available on the company’s website not earlier than six weeks and not more than four weeks prior to the Meeting date. The Nomination Committee will prepare and submit proposals regarding: · election of and fees to the Chairman of the Board and other Board members · election of and fees to the auditors and deputy auditors · resolution on principles governing the composition of the Nomination Committee · Chairman of the AGM Shareholders who wish to submit proposals may do so in writing to the Nomination Committee by e-mail: info.investor@sectra.se, or by mail: Sectra AB, Attn. Nomination Committee, Teknikringen 20, SE-583 30 Linköping, Sweden. The information was submitted for publication, through the agency of the contact person set out below, at 8:10 a.m. CET on December 7, 2016.  

Knorr-Bremse announces outcome and receives strong support for offer to Haldex shareholders

· Acceptance level of 86.1 percent including shares already held by Knorr-Bremse · Acceptance period extended until 28 February 2017 · Full commitment to pursue merger control process – EU referral granted and US filing submitted “We are delighted about the strong support by investors. It confirms the attractiveness of our offer and also the strategic rationale of the proposed business combination. Haldex represents a strong addition to Knorr-Bremse and a highly valued asset for our combined group. We are convinced that we will be able to create numerous advantages for all stakeholders, including employees, customers and business partners,” said Klaus Deller, Chairman of the Executive Board of Knorr-Bremse. “We will continue to work with full commitment on the merger control process where we have achieved two important milestones already. Based on the open dialog with the authorities we are confident that we will obtain all necessary merger control approvals.” On 5 September 2016, Knorr-Bremse AG (“Knorr-Bremse”) announced a public offer to the shareholders of Haldex AB (publ) (“Haldex”) to tender all shares in Haldex to Knorr-Bremse (the “Offer”). The shares tendered in the Offer at the end of the acceptance period on 5 December 2016, together with the shares already held by Knorr-Bremse, amount to in aggregate 38,072,860 shares in Haldex, corresponding to 86.1 percent of the share capital and voting rights in Haldex. The completion of the Offer is conditional upon, inter alia, the Offer being accepted to such extent that Knorr-Bremse becomes the owner of more than 50 percent of all shares in Haldex and all necessary clearances from authorities are obtained. Thus, the minimum acceptance level condition is currently met but remains until the Offer is declared unconditional. Knorr-Bremse has already been granted a request for referral to the EU Commission and thereby entered the pre-notification phase in the European Union. In addition, Knorr-Bremse has submitted the necessary filing under the HSR Act in the United States. To achieve merger control approvals, a longer merger clearance period has proved necessary. Thus, this condition is not yet met and Knorr-Bremse will revert with more details as appropriate. In view of the longer clearance period and to allow further shares to be tendered, Knorr-Bremse has decided to extend the acceptance period until and including 28 February 2017, 5:00 pm (CET). Settlement will be initiated as soon as Knorr-Bremse announces that the conditions for the Offer have been fulfilled or Knorr-Bremse otherwise decides to complete the Offer. If such announcement takes place on 3 March 2017, at the latest, settlement is expected to be initiated around 10 March 2017. Knorr-Bremse has outside the Offer acquired in total 6,595,039 shares in Haldex, corresponding to 14.92 percent of the share capital and voting rights in Haldex. None of these shares have been acquired at a price which exceeds the consideration in the Offer. Other than that Knorr-Bremse does not hold any financial instruments that give financial exposure to Haldex shares. At the end of the original acceptance period on 5 December 2016, the Offer had been accepted by shareholders representing in total 31,477,821 shares in Haldex, corresponding to 71.2 percent of the share capital and voting rights in Haldex.Knorr-Bremse AG    For additional information contact: Knorr-Bremse AG Dr. Detlef HugEmail: Detlef.Hug@knorr-bremse.comPhone: +49 89 3547 1402 Eva DopplerEmail: Eva.Doppler@knorr-bremse.comPhone: +49 89 3547 1498 Additional contacts for media in Germany FTI Consulting SCCarolin AmannEmail: Carolin.Amann@fticonsulting.comPhone: +49 69 92037 132 Thomas M. KrammerEmail: Thomas.Krammer@fticonsulting.comPhone: +49 89 71042 2116 Additional contacts for media in Sweden Comir ABJohan HähnelEmail: Johan.Hahnel@comir.sePhone: +46 8 31 17 70 This press release was submitted for publication on 7 December 2016 at 8.15 a.m. CET.     Important noticeThe Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national security exchange, of Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Accordingly, this announcement and any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. This announcement is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa must not forward this announcement or any other document received in connection with the Offer to such persons. Statements in this announcement relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Knorr-Bremse AG. Any such forward-looking statements speak only as of the date on which they are made and Knorr-Bremse AG has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. Special notice to shareholders in the United States  The Offer described in this announcement is made for shares of Haldex AB, a company incorporated under Swedish law, and is subject to Swedish disclosure and procedural requirements, which are different from those of the United States. The Offer is made in the United States in compliance with Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act"), subject to the exemptions provided by Rule 14d-1(d) under the U.S. Exchange Act and otherwise in accordance with the requirements of Swedish law. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to withdrawal rights, the offer timetable, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws. To the extent permissible under applicable law or regulation, Knorr-Bremse AG and its affiliates or brokers (acting as agents for Knorr-Bremse AG or its affiliates, as applicable) may from time to time, and other than pursuant to the Offer, directly or indirectly purchase, or arrange to purchase, shares of Haldex AB, that are the subject of the Offer or any securities that are convertible into, exchangeable for or exercisable for such shares. To the extent information about such purchases or arrangements to purchase is made public in Sweden, such information will be disclosed by means of a press release or other means reasonably calculated to inform U.S. shareholders of Haldex AB of such information. In addition, the financial advisors to Knorr-Bremse AG, may also engage in ordinary course trading activities in securities of Haldex AB, which may include purchases or arrangements to purchase such securities. Knorr-Bremse AG and/or its affiliates or brokers have purchased shares of Haldex AB during the period following the announcement of the Offer on 5 September 2016. NEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THIS OFFER, PASSED UPON THE FAIRNESS OR MERITS OF THIS ANNOUNCEMENT OR DETERMINED WHETHER THIS ANNOUNCEMENT IS ACCURATE OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE IN THE UNITED STATES.

Mexican publisher signs agreement with Cxense for personalization offering

Oslo, Norway – 7 December 2016 – Cxense ASA (OSE: CXENSE) today announced that Empresas El Debate, SA de C.V. has signed an agreement with Cxense for the use of its Data Management and Personalization Software.El Debate is the biggest publisher in northern Mexico with daily coverage of local news for the states of Mazatlán, Sinaloa, Sonora, Durango, Baja California and Nayarit. The company also provides international-, sports- and entertainment news, as well as classifieds. El Debate has been active in reaching out to digital readers introducing app-based services in 2011.The company has licensed Cxense DMP and Cxense Content. El Debate will use the personalization offering to improve audience selling, enhance the group’s advertising strategy and drive user engagement. Cxense will in addition provide digital strategy consulting services.About Cxense:Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide.Customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, Ebay, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, South China Morning Post, AEON, DMM, Rakuten and many more. For more information: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE.'Investor Relations Contact:Jørgen Loeng, Chief Financial OfficerEmail: jorgen.loeng@cxense.comMobile: +47 906 60 062

Alma Media has selected Cybercom as its Amazon Web Services (AWS) partner

“Developing digital capabilities in media services is an ongoing and continuous process. Efficient and agile utilisation of cloud platforms opens up new opportunities for our media and service brands. Cybercom's cloud platform expertise is excellent and we trust their ability and their experience as an AWS support service provider,” says Simo Syrjänen, CTO, Alma Media. Alma Media is a media company focusing on the service business and journalistic content. The company's best-known brands are Kauppalehti, Talouselämä, Affärsvärlden, Iltalehti, Aamulehti, Etuovi.com and Monster. Alma Media builds sustainable growth for its customers by utilising the opportunities of digitality, including information services, system and expert services and advertising solutions. Alma Media's operations have in the recent years expanded from Finland to the Nordic countries, the Baltics, and Central Europe. “This agreement with Alma Media is the next step in the growth of our Passionate Support for AWS support service. The functionality of Cybercom's long-term client strategy and collaboration based on partnership played a key role in the agreement struck with Alma Media. Our collaboration is well established and we are now happy to take the next step in the support services for the AWS cloud platform,” says Veli-Matti Nurminen, Managing Director, Cybercom Finland. Amazon Web Services is one of Cybercom's key cloud partners. Cybercom is an AWS Advanced Consulting Partner and an official reseller in the public and private sectors. 

Paper bags are the low-carbon choice, new study finds

EU citizens use an average of 200 plastic bags a year, many of which are used in the current Christmas shopping period. Lots of plastic bags are only used once and end up in landfill. A Swedish life cycle analysis carried out by IVL Swedish Environmental Institute has now shown that the carbon footprint of a carrier bag made from recycled plastic is twice that of a paper bag made by material from BillerudKorsnäs. “The company uses a significant proportion of renewable energy in its production. That contributes considerably to paper bags made by their materials having the smallest carbon footprint,” said Lena Dahlgren, project manager at IVL. BillerudKorsnäs is a Swedish company that aims to be a leader in the transition to a sustainable society. The company produces low-carbon packaging material based on responsibly managed forests in the Nordic region and is now encouraging retailers across Europe to reduce their carbon footprint. “The study clearly shows the advantages of our bio-based material and our energy-efficient production. We now know with certainty that our product has significant climate benefits over other materials,” said Henrik Essén, SVP Communication & Sustainability at BillerudKorsnäs. An EU directive from last year requires a reduction in the number of plastic bags. The EU’s main aim is to reduce the number of plastic bags being thrown away. But the new study shows that switching to paper bags also offers lower carbon emissions. “The results of this study now offer retail chains the opportunity to review their carrier bag offering and choose low-carbon bags, and we can be part of that solution,” said Henrik Essén. Read the full report here: http://www.billerudkorsnas.com/lifecycleassessment

SAS traffic figures - November 2016

Market developmentAlthough the demand is growing, the operating environment has become more challenging. As noted previously, the yield has declined more than anticipated during 2016. In addition, during the autumn jet fuel prices have started to increase combined with an unfavorable USD appreciation versus the SEK. This has had a negative effect on working capital and earnings. In addition, the introduced aviation tax in Norway has had a negative effect on the yield development. The total capacity increase in 2015/16 amounts to 10%. In 2016/2017, SAS’s total capacity increase will be lower. The increase will primarily be driven by a full-year effect from the new intercontinental routes that commenced during 2015/2016, increased capacity on leisure routes and the fact that the Airbus A320neo is larger than the aircraft it will replace. SAS scheduled traffic development in NovemberSAS increased its scheduled capacity in November by 10.4% and the traffic grew 17.3%. The overall load factor was 73.7%, the highest November load factor recorded for SAS. The improvement was driven by positive development on SAS’s intercontinental routes and international routes within Europe. SAS intercontinental traffic increased 29.4% and the capacity was up 21.8%. The growth was driven by the new routes to/from Los Angeles and Miami. The traffic on the European/Intrascandinavian routes increased by 13.6%. The growth was strongest on leisure oriented routes. On domestic routes, the capacity was increased by 1.6% and the traffic was up by 3.5%.

EQT Infrastructure enters strategic partnership with GETEC

· EQT Infrastructure to acquire a majority shareholding in three subsidiaries of GETEC ENERGIE HOLDING GmbH · EQT Infrastructure to support continued development of the subsidiaries GETEC heat & power AG, GETEC WÄRME & EFFIZIENZ AG und GETEC media AG · Partnership creates strong platform to build upon market position and continue geographical expansion The EQT Infrastructure investment strategy (“EQT Infrastructure”) has entered a strategic partnership with GETEC. The partnership will jointly develop the companies GETEC heat & power AG, GETEC WÄRME & EFFIZIENZ AG und GETEC media AG (together ”the Companies”) under a newly formed joint venture company. EQT Infrastructure will own 60 percent of the joint venture company. GETEC was founded by Dr Karl Gerhold in 1993 and is today one of the market leaders in energy services in Germany. The GETEC brand stands for tailor-made, efficient and sustainable energy solutions, implemented by a group of highly qualified engineers. The group currently operates around 1,050 decentralized energy production plants in Germany. In 2015, GETEC reported sales of EUR 783 million and employed 1,165 people. The aim of the partnership is to further strengthen and expand the activities of the jointly owned Companies. The strategy includes identifying and capturing growth opportunities both in Germany and by expanding into neighboring markets. Dr Karl Gerhold, owner and Managing Director of GETEC said: ”We are happy to partner with such an experienced investor and owner such as EQT Infrastructure. They have a stellar track record of developing companies and their experience and network of industrial experts in the energy sector is impressive. Together, we believe we now have the very best prerequisites to make the Companies even stronger.” Matthias Fackler, Partner at Investment Advisor EQT Partners, said: “Decentralized energy production is a crucial element of the new energy market and its importance will continue to increase in the future. GETEC is very well placed to profit from this trend thanks to a strong market position and outstanding technical capabilities. We are very much looking forward to support further development of the Companies and to explore expansion opportunities together with Dr Gerhold and the existing GETEC management team.” The transaction is subject to merger clearance from European competition authorities and is expected to close in the first quarter of 2017. Contacts: Matthias Fackler, Partner at EQT Partners in Germany, Investment Advisor to EQT Infrastructure, +49 89 2554 99520 Kerstin Danasten, EQT Press Officer, +46 8 506 55 334 About EQT EQT is a leading alternative investments firm with approximately EUR 30 billion in raised capital. EQT Funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com About the GETEC companies GETEC heat & power AG offers energy service solutions for industrial customers, municipalities and large complex real estate owners. As part of its business the company develops, builds, finances and operates innovative and highly efficient energy production plants. GETEC WÄRME & EFFIZIENZ AG offers energy service solutions for real estate owners and operators. This includes residential, commercial and public real estate, hotels as well as social buildings such as hospitals or care homes. GETEC media AG offers telecom services as well as implementation and operation of data transport infrastructure for the real estate sector. More info: www.getec.de

Vattenfall’s wireless charging station inaugurated on new electric bus route

This is the first time in the Nordic region that a hybrid electric bus running on a regular route is being provided with invisible inductive charging. Seven minutes of wireless charging is enough for bus route 755 to run its entire distance of ten kilometres. The experience gained in this project will be important for the public transport of the future. “This cooperation is a tangible example of realising Vattenfall’s strategy. The further electrification of the transport sector is one of the most important contributions to a climate-neutral Sweden. A hundred years ago, Vattenfall electrified Sweden and the railways, and now we are electrifying the road transports,” says Magnus Hall, CEO and President of Vattenfall. Vattenfall owns and operates the charging station and supplies it with renewable electricity. Wireless bus stop charging means that the bus parks over a charging segment hidden in the road where charging takes place automatically. This charging solution is based on wireless inductive technology which is safe, efficient and environmentally friendly. Sweden aims to have a fossil-free vehicle fleet by 2030. The electrification of public transport, and buses in particular, is crucial to reach this goal. The hybrid electric bus is 70 per cent more energy-efficient than a corresponding conventional diesel bus."Vattenfall wholeheartedly supports the objective of reducing emissions from the transport sector and it is a part of the company’s future to offer customised charging infrastructure for electric buses,” says Hall.  For further information, please contact:Michelle von Gyllenpalm, Head of PRA & Media Relations, phone: +46 70-531 63 11 From Vattenfall’s Press Office, telephone: +46 8 739 5010

Scania tests fast wireless charging in urban traffic

  This is the first time the technology is being tested in the Nordic region and both the bus and bus stop solution are part of a research project where Scania, the public transport operator for the Stockholm region SL, Vattenfall, Södertälje Municipality and the Royal Institute of Technology (KTH) are cooperating to develop a silent and sustainable public transport system. The project is partly financed by the Swedish Energy Agency.   For the first time ever, this type of technology is also being tested for a more extreme climate, which this type of infrastructure must also cope with to be relevant in more northerly parts of the world. Wireless bus stop charging means that the bus parks over a charging segment located under the road surface at the charging station, where charging occurs automatically. The design of the inductive technology has been adapted so as not to disturb existing urban environments and is essentially invisible. Seven minutes of wireless charging is enough to cover the entire 10 km-long route, which the bus will operate in Södertälje. “The electric hybrid bus in this project demonstrates a technology track for a more sustainable transport solution. The inductive charging technology is both silent and invisible. The field test in Södertälje is important ahead of the choices facing both society and the automotive industry with regard to eliminating emissions and reducing noise from traffic in sensitive urban environments,” says Hedvig Paradis, who is a project manager at Scania and responsible for the company’s participation in the research project. The cost of the Wireless bus stop charging project amounts to just over SEK 38 million, of which Scania is investing SEK 22 million. The Swedish Energy Agency has granted almost SEK 10 million in research funding, which will be divided among the Royal Institute of Technology, Scania and SL. “This is one of several projects Scania is conducting in order to find solutions for future sustainable transport services in cities,” says Anders Grundströmer, Head of recently started Scania Sustainable City Solutions. “We are working on identifying the needs of cities and on creating systems for eco-friendly, fast, secure and cost-effective transport solutions, which are based on locally-produced alternative fuels including electrification.”   Electrification of the transport sector will demand various technologies and solutions – both in terms of where and how vehicles are charged. Charging can either occur when vehicles are stationary at depots and bus stops or during operation. For charging during operation the alternatives are conductive charging via a pantograph or inductive charging – or a combination of these techniques. The choice of solution depends on what transport task will be performed. The size and weight of the batteries, which can be carried on board the vehicle, for example, determines how much of the charging must occur while in service. The bus that Scania will test in Södertälje’s urban traffic is a hybrid bus, i.e. featuring technology, which means that the bus’s batteries are also charged during operation by utilising braking power. Charging may also occur using the bus’s combustion engine, which operates on fossil-free fuel. More information about Scania’s electrification is available on www.scania.com/electrification For further information, please contact Karin Hallstan, Public Relations Manager,  tel. +46 76 842 81 04. Technical facts about the bus: Model: Scania Citywide LE4x2Powertrain: Parallel hybrid, integrated with the   gearbox (GRS895)Electrical 130 kWengine,capacity:Battery: Li-Ion 56 kWhCombustion 9-litre 320 hp diesel engine (operates on biodiesel)engine:

Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States

Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) and Horizon Pharma plc (NASDAQ: HZNP) (“Horizon”) today announced that the companies have entered into a five-year distribution agreement for Ravicti® (glycerol phenylbutyrate) in European countries, including United Kingdom, Germany, France, Italy and Spain and for Ammonaps® (sodium phenylbutryate) in the same European countries and certain Middle Eastern countries.  Under the agreement, Sobi will have exclusive marketing, sales and distribution rights for the two medicines in the territory until 31 December 2021. Horizon has the ability to terminate the agreement after two years subject to certain pre-defined termination fees.  Sobi currently distributes Ravicti in certain Middle Eastern countries and Ammonaps in certain European and Middle Eastern countries. Ravicti and Ammonaps are authorised by the European Commission and are indicated for the treatment of Urea Cycle Disorders (UCD). “We are happy to build on our successful relationship with Horizon Pharma to support providing treatment to people living with UCDs”, says Alan Raffensperger, Chief Operating Officer of Sobi and continues:  “This distribution agreement will allow us to leverage our existing expertise and extensive experience within the area of UCDs.  Our main focus now will turn to implementing patient access activities with the objective to launch Ravicti in Europe during 2017.” “Sobi has been a trusted partner in Europe and the Middle East for the last three years,” says Francoise de Craecker, group vice president and general manager, EMEA, orphan business unit, Horizon Pharma plc.  “We believe that Sobi's current distribution of Ammonaps uniquely qualifies it to effectively provide Ravicti to people living with UCDs in European markets.” _________ About Ravicti® Ravicti is indicated for use in all 28 Member States of the European Union and 3 Member States of the European Economic Area as a nitrogen-binding agent for chronic management of adult and pediatric patients two months of age and older with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Important Safety Information LIMITATIONS OF USE:  · Ravicti is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels. · The safety and efficacy of Ravicti for the treatment of patients with N-acetylglutamate synthase (NAGS) and CITRIN (citrullinaemia type 2) deficiency has not been established. · The use of Ravicti in patients <2 months of age is not recommended as the safety and efficacy of Ravicti in this age group has not been established. CONTRAINDICATIONS:  · Hypersensitivity to the active substance. · Treatment of acute hyperammonaemia.  WARNINGS AND PRECAUTIONS:  · Phenylacetate acid (PAA), the major metabolite of Ravicti, may be toxic at levels ≥500 µg/mL. Reduce Ravicti dosage if symptoms of neurotoxicity, including vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses. · Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of Ravciti and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely. · Studies in animals have shown reproductive toxicity (see section 5.3). There are limited data regarding the use of glycerol phenylbutyrate in pregnant women. Glycerol phenylbutyrate is not recommended during pregnancy and in women of childbearing potential not using contraception. · It is unknown whether glycerol phenylbutyrate or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from glycerol phenylbutyrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. ADVERSE REACTIONS:  · Assessment of adverse reactions was based on exposure in 114 UCD patients (65 adults and 49 children between the ages of 2 months and 17 years) with deficiencies in CPS, OTC, ASS, ASL, ARG, or HHH across 4 short term and 3 long term clinical studies, in which 90 patients completed 12 months duration (median exposure = 51 weeks). · At the beginning of the treatment, abdominal pain, nausea, diarrhoea, and/or headache may occur; these reactions usually disappear within a few days even if treatment is continued. The most frequently reported adverse reactions (>5%) during glycerol phenylbutyrate treatment were diarrhoea, flatulence, and headache (8.8% each); decreased appetite (7.0%), vomiting (6.1%); and fatigue, nausea and, skin odour abnormal (5.3% each). DRUG INTERACTIONS:  · Concomitant use of medicinal products known to inhibit lipase should be given with caution as glycerol phenylbutyrate is hydrolysed by digestive lipase into phenylbutyrate acid and glycerol. This may be associated with increased risk of medicinal product interactions with lipase inhibitors and with lipase contained in pancreatic enzyme replacement therapies. · A potential effect on CYP2D6 isoenzyme cannot be excluded and caution is advised for patients who receive medicinal products that are CYP2D6 substrates. · Glycerol phenylbutyrate and/or its metabolites, PAA and PBA, have been shown to be weak inducers of CYP3A4 enzyme in vivo. In vivo exposure to glycerol phenylbutyrate has resulted in decreased systemic exposure to midazolam of approximately 32% and increased exposure to the 1-hydroxy metabolite of midazolam, suggesting that steady-state dosing of glycerol phenylbutyrate results in CYP3A4 induction. The potential for interaction of glycerol phenylbutyrate as a CYP3A4 inducer and those products predominantly metabolised by the CYP3A4 pathway is possible. Therefore, therapeutic effects and/or metabolite levels of medicinal products, including some oral contraceptives that are substrates for this enzyme may be reduced and their full effects cannot be guaranteed, following coadministration with glycerol phenylbutyrate. · Corticosteroids, valproic acid, haloperidol and probenecid may have the potential to affect ammonia levels. About Ammonaps®Ammonaps (sodium phenylbutyrate) is used to treat Urea Cycle Disorders (UCD). UCD is a group of serious conditions in which patients suffer from deficiencies in the enzymes required to remove ammonia from the blood stream.Ammonaps is used to reduce levels of ammonia and glutamine in the blood. Ammonaps is used with other treatments and a special diet for the long-term management of patients with urea cycle disorders where there is lack of one or more of the following enzymes: carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinate synthetase. Ammonaps is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. Important Safety Information  CONTRAINDICATIONS:  · Pregnancy. · Breast-feeding. · Hypersensitivity to the active substance or to any of the excipients WARNINGS AND PRECAUTIONS: · Ammonaps tablets should not be used in patients with dysphagia due to the potential risk of oesophageal ulceration if tablets are not promptly delivered to the stomach. Each Ammonaps tablet contains 62 mg (2.7 mmol) of sodium, corresponding to 2.5 g (108 mmol) of sodium per 20 g of sodium phenylbutyrate, which is the maximum daily dose. Ammonaps should therefore be used with caution in patients with congestive heart failure or severe renal insufficiency, and in clinical conditions where there is sodium retention with oedema.  · Ammonaps granules contain 124 mg (5.4 mmol) of sodium per gram of sodium phenylbutyrate, corresponding to 2.5 g (108 mmol) of sodium per 20 g of sodium phenylbutyrate, which is the maximum daily dose. Ammonaps should therefore be used with caution in patients with congestive heart failure or severe renal insufficiency, and in clinical conditions where there is sodium retention with oedema.  · Since the metabolism and excretion of sodium phenylbutyrate involves the liver and kidneys, Ammonaps should be used with caution in patients with hepatic or renal insufficiency.  · Serum potassium should be monitored during therapy since renal excretion of phenylacetylglutamine may induce a urinary loss of potassium.  · Even on therapy, acute hyperammonaemic encephalopathy may occur in a number of patients.  · Ammonaps is not recommended for the management of acute hyperammonaemia, which is a medical emergency.  · In children unable to swallow tablets, it is recommended to use Ammonaps granules instead.                         ADVERSE REACTIONS:  · In clinical trials with Ammonaps, 56 % of the patients experienced at least one adverse event and 78 % of these adverse events were considered as not related to Ammonaps. · Adverse reactions mainly involved the reproductive and gastrointestinal system. DRUG INTERACTIONS:  · Concurrent administration of probenecid may affect renal excretion of the conjugation product of sodium phenylbutyrate. · There have been published reports of hyperammonaemia being induced by haloperidol and by valproate. Corticosteroids may cause the breakdown of body protein and thus increase plasma ammonia levels. More frequent monitoring of plasma ammonia levels is advised when these medications have to be used. About Sobi™ Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and   Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.   About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com (http://file///C:/Users/e011271/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/FHXQBXL5/www.horizonpharma.com).  Follow @HZNPplc (http://ctt.marketwire.com/?release=1199271&id=6291790&type=1&url=https%3a%2f%2ftwitter.com%2fhznpplc) on Twitter or view careers on our LinkedIn (http://ctt.marketwire.com/?release=1199271&id=6291793&type=1&url=https%3a%2f%2fwww.linkedin.com%2fcompany%2fhorizon-pharma) page.  Forward Looking StatementsThis press release contains forward-looking statements, including statements regarding the potential benefits that may be derived from the distribution agreement between Horizon Pharma and Sobi, and plans and expected timing with respect to launching Ravicti in Europe.  These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors.  These factors include risks that the distribution agreement is terminated early, that either party does not comply with its obligations under the distribution agreement, that adequate pricing and reimbursement for Ravicti in Europe is not available, and those factors described in Horizon Pharma's filings with the United States Securities and Exchange Commission, including those discussed under the caption "Risk Factors" in those filings.  Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.  For more informationplease contact:Media relations Investor relationsLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor RelationsT: + 46 708 73 40 95, + T: +1 347-224-0819, +1 21246 8 697 31 74   -579-0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com  Horizon Pharma contacts:Media  Investor relations Geoff Curtis  Tina Ventura Senior Vice President, Senior Vice President,Corporate Investor Relations Communications media@horizonpharma.com  Investor -relations@horizonpharma.com

EQT Mid Market invests in Fertin Pharma A/S

· EQT Mid Market acquires Fertin Pharma, the world’s largest independent developer and manufacturer of medicated chewing gum · The founding Bagger-Sørensen family will reinvest and enter into a partnership with EQT Mid Market with the view to further develop and accelerate the growth of Fertin Pharma · The management team of Fertin Pharma, led by CEO Søren Birn, will remain with the Company and invest alongside the Bagger-Sørensen family and EQT Mid Market EQT Mid Market has agreed to acquire Fertin Pharma (“Fertin Pharma” or the “Company”) from the Bagger-Sørensen family. The Bagger-Sørensen family will reinvest part of their proceeds and will following the transaction own 30% of the Company. The Company is the leading independent B2B developer and manufacturer of medicated chewing gum, primarily within Nicotine Replacement Therapy (“NRT”), a pharmaceutical product used for withdrawal management in the process of tobacco cessation. Furthermore, Fertin develops pharmaceutical chewing gum with different APIs (MediChew) and nutraceutical chewing gum products (Nutraceuticals). Rikke Kjær Nielsen, Director at EQT Partners and Investment Advisor to EQT Mid Market, said: “We are truly impressed by Fertin Pharma’s strong management team and its unparalleled market position based on a unique combination of more than 100 years of chewing gum heritage, profound nicotine knowledge and strong pharma manufacturing capabilities. Fertin is a global market leader within NRT gum with a strong financial track record operating in one of EQT’s core sectors and core geographies. As such we see an excellent match with EQT, which is further underpinned by the EQT track record in healthcare investments and experience in supporting companies to drive growth across different avenues. We are therefore extremely pleased about the partnership with the founding family to jointly develop Fertin into an even stronger company”. Søren Birn, CEO of Fertin Pharma, said: “Fertin has developed a global stronghold with its leading NRT gum product portfolio and realized above market growth for several years.We are very pleased to have EQT as our new majority owner and partner in this exciting phase for Fertin. We share the same vision and ambitions for Fertin’s great potential. Under the new partnership, we look very much forward to  continue growing the core business while exploring new avenues of growth for the Company”. Steen and Claus Bagger-Sørensen, main shareholders of Fertin Pharma, said: “We are pleased to have EQT as the new majority owner of Fertin, and we believe they are a great fit with Fertin, both in terms of core values, visions and long-term ambitions for the Company. Furthermore, we are excited about entering a partnership with them, and we look forward to working alongside EQT and contributing knowledge, experience and history”.   Financial terms of the transaction are not disclosed. Contacts: Rikke Kjær Nielsen at EQT Partners, Investment Advisor to EQT Mid Market, +45 4021 1216 Kerstin Danasten, EQT Press Officer, +46 8 506 55 334 About the Bagger-Sørensen family The Bagger-Sørensen family founded Vejle Caramel og Tablet Fabrik in 1915 and launched the Dandy chewing gum brand in 1939. In 1978, the Swedish company Fertin, known for their V6 chewing gum, was acquired by the Bagger-Sørensen Group. Following the acquisition the company was renamed Fertin Pharma and in 2000 Fertin Pharma launched the world’s first coated nicotine gum. Today, the family brothers Steen and Claus Bagger-Sørensen, along with the family fund, comprise the owners of Fertin Pharma prior to the transaction. About EQT EQT is a leading alternative investments firm with approximately EUR 31 billion in raised capital. EQT Funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com About Fertin Pharma Fertin Pharma A/S is a family-owned company based in Vejle, Denmark, with additional facilities in India. Fertin is the world’s leading B2B developer/manufacturer of medicated chewing gum, specialising in Nicotine Replacement Therapy gum. Fertin has 715 employees and an estimated 2016 revenue of DKK 851m and EBITDA of DKK 250m. More info: www.fertin.com 

Saab Signs Contract for Torpedo Integration Systems with FMV

The contract includes construction, production and verification of Torpedo Integration Systems for the two A26 submarines which were ordered by the Swedish Defence Materiel Administration in 2015. In addition, Saab will also upgrade existing Torpedo Integration Systems on the Visby-class corvettes and Gotland-class submarines. The contract also includes options for future upgrade orders. “With this contract, the Swedish Navy will have modern Torpedo Integration Systems on their submarines and corvettes to ensure a continued and modern operation of the existing torpedo systems”, says Anne-Marie Vösu, head of business unit Underwater Systems within Saab business area Dynamics.  “With the new systems, the corvettes and submarines will also be prepared for the Swedish Navy´s New Lightweight Torpedo, ordered in 2016 and now under development by Saab. The systems also supports the integration of Saab´s AUV´s and ROV´s on the platforms”, says Anne-Marie Vösu.  Saab has over the years established a unique experience and expertise in developing underwater systems including specially adapted propulsion, communications and seekers, for operations in shallow waters and the types of environments that exists in the Baltic Sea. Saab is a longstanding supplier to FMV and has provided underwater solutions for weapon systems, sensors, autonomous and remotely operated underwater vehicles and mine hunting. For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Moberg Pharma completes tap issue of SEK 215 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, NEW ZEELAND, SOUTH AFRICA, HONG KONG OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL The tap issue has been placed at a price of 102.75 per cent of the nominal amount, indicating an interest rate of Stibor 3m + 5.27 per cent when applying a Stibor-floor at 0. After the tap issue, the total outstanding amount of the company’s bond loan will amount to SEK 600M, which equals the total framework amount of the bond loan. The bond loan is listed on Nasdaq Stockholm and the company will apply for listing of the new bonds on Nasdaq Stockholm. The settlement date of the tap issue is set to December 14th, 2016. The issuance of the new bonds means that Moberg Pharma utilizes the waiver obtained from the bondholders. The consent fee of 0.5 per cent of the today outstanding nominal amount of the bonds will be paid to directly registered owners and registered authorised nominees (Sw. förvaltare) of the bonds as of December 12th, 2016 in the debt ledger produced by Euroclear Sweden. The payment is expected to be made on December 19th, 2016. Any individual or company whose bonds are held by a nominee receives the consent fee through such nominee. “We highly appreciate the support provided by our bondholders and the large interest for this tap issue. As a result, the issue has been placed at a premium to the nominal amount and we have secured the capital needed to complete the acquisition of DermoPlast®. From January 2017, DermoPlast® is expected to contribute significantly to our profitability and operative cash flow”, says Peter Wolpert, CEO of Moberg Pharma. Carnegie Investment Bank and Swedbank have been engaged as financial advisors and Gernandt & Danielsson as legal advisor in conjunction with the tap issue. About this information              This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 3.00 p.m. (CET) on December 7th, 2016. 

Gaming Corps & PDP sign agreement to develop prototypes showcasing breakthrough technology

Gaming Corps has signed an agreement with Performance Designed Products to develop a series of prototypes showcasing a new breakthrough technology. The prototypes will be developed during 2016’s last quarter in Gaming Corps recently acquired Red Fly Studio and could lead to additional developments with PDP. “We are delighted that PDP chose Red Fly, now owned by Gaming Corps as its preferred studio to develop new video games based on its breakthrough technology” - Magnus Kolaas, CEO, Gaming Corps. About Performance Designed Products Performance Designed Products is the #1 video game accessory company in North America. Their passion is to design and develop products that help consumers engage and interact with the entertainment they love. PDP’s industry leadership is due to engineering expertise and experience developing advanced technology. About Gaming Corps Gaming Corps is a Swedish Game Developer who recently acquired Red Fly Studio, an Austin, Texas game developer founded in 2005, known for artistic vision, design innovation, and technical expertise, with decades of experience at prestigious game companies. Red Fly has worked extensively in Unreal, Unity, and Infernal, and has developed on Xbox One, PS4, Xbox 360, PS3, PC, iOS, Android, 3DS, and Wii. Gaming Corps:                                       PDP Media Contact: Magnus Kolaas, CEO                              Amber McCollom magnus.kolaas@gamingcorps.com        Zebra Partners Mobile: +46-708-777 303                        amber@zebrapartners.net                                                                 +1 (206) 353-4751 (http://tel:%28206%29%20353-4751)  

Enersize selects Sedermera Fondkommission as advisor for planned listing on Nasdaq Stockholm First North during 2017

The listing process starts directly and exact information will follow in an investor memorandum to be published later. Enersize recently added one large Chinese glass manufacturer to its project list after previously announcing orders in both the Chinese vehicle and electronics sector. Christian Merheim, Chairman of the Board Enersize, comments: “With an attractive case we had a large selection of advisors to choose from. We are very happy to announce that we choose Sedermera. We had our initial discussions with them over a year ago and we have been impressed with their thoroughness, professionality and integrity all along the way. Enersize team is really looking forward working together with Sedermera for the 2017 IPO". Sami Mykkänen, Enersize CEO, comments: “The timing to start our IPO process could not have been better. During the last year, we have more than tripled the size of our sales pipeline and closed several significant customers. The upcoming IPO gives us the possibility to take on even more projects".  Cleantech Invest, the largest owner of Enersize, CEO Alexander Lidgren comments: “We are happy to be one step closer to offering a listed share in what we think is a carbon cutting champion. After hard and systematic efforts building a big customer pipeline, Enersize is now delivering what can only be labelled drastic energy savings to the Chinese manufacturing industry.” Sedermera Fondkommission’s Head of Corporate Finance, Andreas Sandgren, comments: ”We are delighted to have been appointed Enersize’s advisor and look forward to initiating the listing process of the company.” About Sedermera Fondkommission: Sedermera Fondkommission offers services for listed companies or companies with the target of being listed at a trading platform. Sedermera’s services includes corporate finance, certified adviser, M&A’s, financial communications, issue management and market making. Sedermera is a secondary name of ATS Finans AB, an investment firm under the supervision of the Swedish FSA (Finansinspektionen). Sedermera’s headquarter is in Malmö, Sweden. The company also have offices in Lund (Medicon Village) and Norrköping (Norrköping Science Park). The organisation consists of approximately fifteen co-workers. Sedermera’s ambition is to create long term client and investing relations.

BillerudKorsnäs explores new technologies – launches full scale tests adding MFC to its paperboard

Recent development has allowed for industrial scale extraction of the components of cellulosic fibres in wood, the fibrils. For a paper and board maker, adding microfibrillated cellulose, MFC, in the production process opens up opportunities for new functionality and for further improved resource efficiency. To explore these opportunities, BillerudKorsnäs has during 2016 carried out small scale testing in full production. Based on the results of these initial tests, the company has now decided on full scale trials to start in early 2017. BillerudKorsnäs’ short term aim is achieving the same strength properties of its paperboard products, but with lesser material, so called light weighting. For the future, using MFC could possibly also be a key to replace the thin barrier layers of plastics or aluminium today often added to the otherwise renewable fibre based packaging. The full scale trials are made possible through a new cooperation with Borregaard, a global leader in biorefinery innovation. Under this cooperation, BillerudKorsnäs will be supplied with MFC from the recently started MFC plant of Borregaard in Sarpsborg, Norway. “By adding MFC we want to explore how to further improve our world class materials to make them even more competitive against their main competitor, fossil based plastic packaging. That is how we increase our positive contribution from a sustainability standpoint. We are enthusiastic over our cooperation with Borregaard and with them as our supplier of MFC in this development program”, says Magnus Wikström, CTO at BillerudKorsnäs. “Borregaard welcomes this cooperation with BillerudKorsnäs. Our Exilva MFC products have excellent strength and barrier properties and should hence be good materials for BillerudKorsnäs to further develop their position as a world leader in sustainable packaging solutions, says Pål Romberg, Excecutive Vice President Exilva. Borregaard has used more than 10 years to develop the Exilva MFC technology and is the first company in the world to commercialize MFC through its new 1.000 ton plant which started in Q3 this year.  

Ripasso Energy AB – license applications information and revenue forecast for 2018

At the time of the information memorandum, i.e. November 23, 2016, Horizon had submitted applications for 16 projects with an aggregated sales potential of 106 hybridized Stirling engines (“engines”). Since that date until December 6, 2016, Horizon has submitted additional applications. This means that as of today, there are pending applications for 22 projects, including 125 engines. In addition to the pending applications, Horizon expects to submit applications for an additional 20 projects including 67 engines before end of 2016.  With respect to the pending applications: · 8 projects including 55 engines have been approved for grid connection. · 4 projects including 39 engines have been declined grid connection. · 10 projects including 31 engines await decision.  The grid connection approval is an important step in the application process. The projects approved for grid connection now await decisions from regional authorities. Declined projects are not likely to materialize. Approved projects are expected to be fully ready for investment between April and August 2017. A firm order to Ripasso Energy is expected in September 2017. Final delivery of the first projects is planned for Q1 2018. During 2018, Ripasso Energy forecasts completed delivery of at least 100 engines, resulting in Ripasso Energy’s share of revenues being 4.8 MEUR with a positive gross margin. During 1H 2017, Ripasso Energy and Horizon will construct a demonstration unit on the grounds of University of Palermo. The objective is to attract interest to invest in projects with Ripasso Energy technology and transfer EPC-knowledge to Horizon in preparation for commercial projects. The target date for completion is May 31, 2017. Part of the construction process will be recorded by Finwire Media and published on YouTube.   For additional information with respect to this press release, please contact Ripasso Energy’s CEO and founder Gunnar Larsson, e-mail: ir@ripassoenergy.com. For more information about the company, visit: www.ripassoenergy.com. This information is information that Ripasso Energy is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 8:30 on December 8, 2016.

Scan Bidco A/S announces pro forma figures for the last twelve months ending on 30 September 2016

Due to, inter alia, the acquisition of Airlog Group Holding AB (“Airlog”), Scan Bidco A/S has decided to publish financial information on a pro forma basis for the operating companies Scan Global Logistics and TransGroup and individual figures for Airlog for the last twelve months ending 30 September 2016 (the “LTM Period”), as well as financial figures for Q3 2016 for Scan Global Logistics and TransGroup. The acquisition of TransGroup took place on 1 October 2016 and the pro forma figures in this press release are presented for the purpose of showing, on an illustrative basis, the effect of consolidating TransGroup during the entire LTM Period. The financial information presented below has not been audited. Moreover, the conversion of the Company’s accounts to IFRS is underway but for interim purposes the financial information for TransGroup and Scan Global Logistics has been prepared in accordance with US GAAP and Danish GAAP for the respective entities. The aggregate adjusted EBITDA for Scan Global Logistics and TransGroup amounted to DKK 231 million during the LTM Period, representing an adjusted EBITDA margin of 4.5 per cent. The holding companies Scan Bidco A/S and Scan Global Logistics Holding ApS generated an aggregate adjusted EBITDA of DKK -8.4 million during the period, resulting in an aggregate pro forma and adjusted EBITDA of DKK 222.6 million. +--------------+-------+--------------------------------------+|Pro forma financials for Scan Global Logistics and TransGroup|+--------------+-------+--------------------------------------+|DKKm |Q3'2016| LTM Sep'2016|+--------------+-------+--------------------------------------+|Gross revenues| 1,228| 5,031|+--------------+-------+--------------------------------------+|Net revenues | 196| 859|+--------------+-------+--------------------------------------+|Adj. EBITDA | 58| 231|+--------------+-------+--------------------------------------+ Net interest bearing debt for Scan Bidco A/S (including TransGroup) was DKK 1,093.7 million as of 30 September 2016.  +-----------------------+------------+|Airlog Group Holding AB| |+-----------------------+------------+|DKKm |LTM Sep’2016|+-----------------------+------------+|Gross revenues | 350|+-----------------------+------------+|Net revenues | 79|+-----------------------+------------+|Adj. EBITDA | 13|+-----------------------+------------+ Airlog generated gross revenues of DKK 350.1 million and an adjusted EBITDA of DKK 13.4 million resulting in an adjusted EBITDA margin of 3.8 per cent.The financial information for Airlog Group Holding is prepared in accordance with Swedish GAAP.Completion of the acquisition of Airlog Group Holding AB is subject to regulatory approval in Denmark and closing is expected in Q1 2017.For more information, please contact:Lars Olsen, Group CFO, Scan Global LogisticsTel: +45 3248 0020, email: laol@scangl.comMaria Hamm, Head of HR, Communication & Compliance, Scan Global LogisticsPhone: +45 3248 0094, e-mail maha@scangl.comAbout Scan Global LogisticsScan Global Logistics is a Nordic based full-service global freight forwarding provider with nearly 800 employees working out of 42 offices in 19 countries, specialised in complex logistics solutions. The Group offers customers a wide range of global transportation and logistics supply chain solutions with a complete coverage on air, sea and overland transportation.

SSAB towards the internet of materials with SSAB SmartSteel

SSAB has recently finalized an R&D project that explores the concept of SSAB SmartSteel, a digital platform that enables the steel to be loaded with knowledge. A unique identity code in the steel plate connecting the plate and information provides customers and their machinery with appropriate data and instructions to help them to select and use SSAB steels, regardless of their application. The idea is to share the expert knowledge in steel that SSAB stands for. “Our vision is a platform built on cloud-based data that contains instructions for different stakeholders in the value chain on how to use our steel,” explains Eva Petursson, Head of R&D at SSAB and continues that “by accessing and adding data on the platform, our customers would be able to make optimal use of the steel and avoid costly and time-consuming failures and misuse. In simple terms, data bring material handling competence where it is needed.” In the pilot R&D project, SSAB, under project leader Seija Junno, worked together with partners including Meyer Turku, Cajo Technologies, Aalto University, VTT Technical Research Centre of Finland Ltd, DIMECC (Digital, Internet, Materials & Engineering Co-Creation) and Academy of Finland’s Strategic Research Council. The first results have been very positive in the area of identifying the plates and finding the corresponding data automatically.   “We are looking for ways to create sustainability‐based added value for our customers, e.g. by telling the carbon footprint or energy consumption during the whole lifecycle of the ship. If steel could provide all the data accumulated during the manufacturing and transportation chain, it would help us significantly and would be the first step towards transparent value chains in our field,” says Jaana Hänninen, Environmental Manager at the Meyer Turku shipyard.  Open invitation to customers and partners SSAB is now ready to further explore the possibilities of the SSAB SmartSteel platform together with more customers and partners and in this respect openly invites all interested customers, process equipment manufacturers and other actors to join the development work. Rapid trials will enable the idea to take shape and  grow clearer.  “We recognize that the only way to fully develop this idea is to co-create with other companies. We think working together is smart - everyone involved wins. We are only just beginning to understand how this can affect everyone in the value chain and ultimately the society we live in,” says Eva Petursson. Contacts for interested customers and partners:Eva Petursson, Head of R&D at SSAB, eva.petursson@ssab.comSeija Junno, Director, Business model development at SSAB, seija.junno@ssab.com  Media information, please contact:Viktoria Karsberg, Head of Corporate Communications, viktoria.karsberg@ssab.com,phone: +46 72 233 5288

Helene Seim new General Manager of Boliden’s Odda zinc smelter

Helene Seim has been appointed General Manager at Boliden’s Odda zinc smelter in Norway. Helene’s most recent position was Production Manager, and she has worked at Boliden Odda since 2003. Helene replaces Dag Berg, who has been General Manager since 2010, and who has been appointed Manager R&D Strategic Projects within Boliden Smelters to strengthen the business unit’s strategic research and development initiatives. They are both, at present, expected to take up their new positions at the start of 2017.“During Dag Berg’s time, Boliden Odda has been involved in a number of successful projects to strengthen its already strong position. With Helene as the new General Manager I am convinced that this positive development will be pursued with a focus on safety and continuous improvements,” says Kerstin Konradsson, President Boliden Smelters.Boliden Odda produces pure zinc and zinc alloys, as well as sulphuric acid. The smelter’s expansion to increase production to 200 ktonnes of zinc per year from the second quarter of 2017 is going well.For more information, please contact:Klas Nilsson, Communications Directortel.: +46 (0)70 453 65 88Kerstin Konradsson, Director, Boliden Smelterstel.: +46 (0)70 378 77 53Boliden is a metals company with a focus on sustainable development. Scandinavian roots, global market. Our core competence lies within the fields of exploration, mining, smelting and recycling. Boliden has about 5,500 employees and an annual turnover of SEK 40 billion. The stock is listed in the Large Cap segment on NASDAQ OMX. Stockholm. www.boliden.com

Change in the reporting of costs related to growth of biological assets

Costs related to the development of biological assets are capitalised on the balance sheet during the growth cycle (i.e. until the time of harvesting). At harvesting, the capitalised costs are transferred from biological assets to inventory. Prior to the change, Stora Enso has included the costs related to the growth of biological assets in its operational EBITDA. Starting from the fourth quarter of 2016, these growth costs will be excluded from operational EBITDA and presented as Operational decrease in the value of biological assets. The reason for the change is to align the reporting of the growth costs with industry benchmarks. This change will affect the following key figures: · operational EBITDA · operational EBITDA margin · net debt to last 12 months’ operational EBITDA ratio There will be no impact on operational EBIT, the subtotals of the official Condensed Consolidated Income Statement or the group’s other IFRS figures. The new definition of the non-IFRS measure of operational EBITDA is: operating profit/loss excluding operational decrease in the value of biological assets, fixed asset depreciation and impairment, share of results of equity accounted investments, IAC and fair valuations. The historical figures are restated according to the new reporting structure and presented in the tables below. RECONCILIATION OF OPERATIONAL PROFITABILITY As published  EUR million Q3/16 Q2/16 Q1/16 2015  Q4/15 Q3/15  Q2/15  Q1/15         Operational 326 333 356 1 352 341 353 318 340EBITDAEquity 17 16 16 80 22 21 24 13accountedinvestments(EAI),operationalDepreciation -124 -123 -124 -517 -121 -128 -135 -133andimpairmentexcl. IACOperational 219  226  248  915  242  246  207  220 EBIT Fair -14 -15 -26 378 401 -25 15 -13valuationsand non-operationalitemsItems -9 37 -28 -234 -250 16 -8 8affectingcomparability(IAC)Operating 196  248  194  1 059  393  237  214  215 profit(IFRS)  Restated  EUR million Q3/16 Q2/16 Q1/16 2015  Q4/15 Q3/15 Q2/15 Q1/15             Operational 343 355 363 1 408 351 369 337 351EBITDAEquity 17 16 16 80 22 21 24 13accountedinvestments(EAI),operationalOperational -17 -22 -7 -56 -10 -16 -19 -11decrease inthevalue ofbiologicalassetsDepreciation -124 -123 -124 -517 -121 -128 -135 -133andimpairmentexcl. IACOperational 219  226  248  915  242  246  207  220 EBIT Fair -14 -15 -26 378 401 -25 15 -13valuationsand non-operationalitemsItems -9 37 -28 -234 -250 16 -8 8affectingcomparability(IAC)Operating 196  248  194  1 059  393  237  214  215 profit(IFRS)  Change  EUR million Q3/1 Q2/1 Q1/1 2015  Q4/1 Q3/15  Q2/15  Q1/15  6  6  6  5 Operational 17 22 7 56 10 16 19 11EBITDAEquity 0 0 0 0 0 0 0 0accountedinvestments(EAI),operationalOperational -17 -22 -7 -56 -10 -16 -19 -11decrease inthevalue ofbiologicalassetsDepreciation 0 0 0 0 0 0 0 0andimpairmentexcl. IACOperational 0  0  0  0  0  0  0  0 EBIT Fair 0 0 0 0 0 0 0 0valuationsand non-operationalitemsItems 0 0 0 0 0 0 0 0affectingcomparability(IAC)Operating 0  0  0  0  0  0  0  0 profit(IFRS)  OPERATIONAL EBITDA BY SEGMENTS  As published  EUR million Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 109 113 108 434 89 116 114 115Packaging Solutions 37 33 23 147 37 32 38 40Biomaterials 71 84 110 420 108 125 87 100Wood Products 30 41 23 111 26 30 32 23Paper 77 74 83 231 74 44 52 61Other 2 -12 9 9 7 6 -5 1Total 326 333 356 1 352 341 353 318 340 Restated  EUR million Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 118 127 110 466 94 128 124 120Packaging Solutions 37 33 23 147 37 32 38 40Biomaterials 79 92 115 444 113 129 96 106Wood Products 30 41 23 111 26 30 32 23Paper 77 74 83 231 74 44 52 61Other 2 -12 9 9 7 6 -5 1Total 343 355 363 1 408 351 369 337 351 Change  EUR million Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 9 14 2 32 5 12 10 5Packaging Solutions 0 0 0 0 0 0 0 0Biomaterials 8 8 5 24 5 4 9 6Wood Products 0 0 0 0 0 0 0 0Paper 0 0 0 0 0 0 0 0Other 0 0 0 0 0 0 0 0Total 17 22 7 56 10 16 19 11 OPERATIONAL EBITDA MARGIN BY SEGMENTS As published  % Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 18.2% 18.9% 19.1% 18.5% 15.9% 19.1% 18.9% 20.2%Packaging Solutions 14.3% 12.8% 9.4% 16.1% 15.4% 14.2% 16.8% 18.1%Biomaterials 21.3% 24.6% 31.3% 28.3% 28.9% 31.9% 23.9% 28.2%Wood Products 7.8% 9.5% 6.0% 6.9% 6.6% 8.0% 7.3% 5.9%Paper 9.7% 8.8% 9.7% 6.4% 8.3% 4.8% 5.7% 6.7%Other 0.4% -1.9% 1.4% 0.4% 1.1% 1.1% -0.8% 0.2%Total 13.6% 13.2% 14.6% 13.5% 13.7% 14.1% 12.4% 13.6% Restated  % Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 19.7% 21.2% 19.5% 19.9% 16.8% 21.1% 20.6% 21.1%Packaging Solutions 14.3% 12.8% 9.4% 16.1% 15.4% 14.2% 16.8% 18.1%Biomaterials 23.7% 26.9% 32.8% 29.9% 30.2% 32.9% 26.4% 29.9%Wood Products 7.8% 9.5% 6.0% 6.9% 6.6% 8.0% 7.3% 5.9%Paper 9.7% 8.8% 9.7% 6.4% 8.3% 4.8% 5.7% 6.7%Other 0.4% -1.9% 1.4% 0.4% 1.1% 1.1% -0.8% 0.2%Total 14.3% 14.1% 14.8% 14.0% 14.1% 14.8% 13.2% 14.1% Change  Percentage point Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 1.5 2.3 0.4 1.4 0.9 2.0 1.7 0.9Packaging Solutions 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Biomaterials 2.4 2.3 1.5 1.6 1.3 1.0 2.5 1.7Wood Products 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Paper 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Total 0.7 0.9 0.2 0.5 0.4 0.7 0.8 0.5 NET DEBT/LAST 12 MONTHS' OPERATIONAL EBITDA RATIO As published  Q3/1 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15 6Net debt/last 12 months' 2.1 2.3 2.3 2.4 2.4 2.5 2.7 2.6operational EBITDA ratio Restated  Q3/1 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15 6Net debt/last 12 months' 2.1 2.2 2.2 2.3 2.3 2.3 2.6 2.5operational EBITDA ratio Change  Q3/1 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15 6Net debt/last 12 months' 0.0 -0.1 -0.1 -0.1 -0.1 -0.2 -0.1 -0.1operational EBITDA ratio For further information, please contact: Ulrika Lilja, EVP Communications, tel. +46 72 221 9228 Investor enquiries:Ulla Paajanen-Sainio, SVP, Investor Relations, tel. +358 40 763 8767  Stora Enso is a leading provider of renewable solutions in packaging, biomaterials, wooden constructions and paper on global markets. Our aim is to replace fossil based materials by innovating and developing new products and services based on wood and other renewable materials. We employ some 26 000 people in more than 35 countries, and our sales in 2015 were EUR 10.0 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY) on the International OTCQX over-the-counter market. storaenso.com (http://www.storaenso.com/)  STORA ENSO OYJ

Cleantech Invest portfolio company Swap.com raises 19M€ round

Cleantech Invest portfolio company Swap.com (Swap.com Services Oy) has closed a 19M€ investment round. The round was led by eEquity from Sweden and joined by other investors. This investment brings Swap.com’s total equity funding to 46M€. The funding will be used to further accelerate the growth of Swap.com. The effective ownership of Cleantech Invest Plc in Swap.com is 5.3% after this investment round. Cleantech Invest Plc and all of its affiliated companies own a total of 16.1% of Swap.com after the transaction. The ownership does not take into account possible dilution from performance based options. Swap.com is an online consignment store that was founded in Finland. The company has been growing 180 % year-over-year, and the company operates a state-of-the-art logistics center of 360,000 square feet in Bolingbrook, Illinois. It has over 1.5 million unique items in stock. CEO of Cleantech Invest, Alexander Lidgren: ”We warmly welcome the new shareholders on board Swap.com. Swap.com aims to become the category leader in the rapidly growing online pre-owned retail market, which is emerging between the traditional online shops such as Amazon and peer-to-peer marketplaces such as eBay. Swap.com is redefining the pre-owned market and changing the way people consume. The investment round is among the largest in the Nordic start-up scene, and reflects the opportunity for a multi-billion dollar business.“ CEO & Co-Founder of Swap.com Services Oy, Dr. Juha Koponen: “As an industry, we’re only scratching the surface. There’s a staggering amount of unused, pre-owned merchandise with an estimated value of more than one hundred billion dollars annually. And while there is a large demand for secondhand items, the merchandise has not been moving mostly because there hasn’t been a practical or convenient way to purchase these items online. With more than 30% of Americans shopping in thrift and consignment stores each year, we have an incredible opportunity to make an impact. This round lead by e-commerce focused eEquity provides us with the resources to scale and become a household name in the United States.” Carnegie Investment Banking acted as a sole financial advisor to Swap.com Services Oy in the private placement. For more information see Swap.com’s press release here (https://www.dropbox.com/s/hxvyi219f9q59bi/2016FundingPressReleaseFI.pdf?dl=0).

TalkPool and Sigma sign global framework agreement within IoT

TalkPool works with advanced technologies and has created a unique leading position in the Low Power Wide Area Technologies (LPWA). This requires credible and stable partners. Sigma Technology is a reliable supplier of technology and software development, with a strong focus on the needs of their customers and high delivery quality. “The new radio technology, optimized for long range and low power consumption, allows for more units to be connected than what was up until now economically viable or even possible. For example, smart homes, containers of various types, pallets and parking lots. It will be fascinating to see what new and exciting areas we will develop that improves our society and gives companies even better offerings”, says Robert Spertina, Head of IoT. Earlier this year, Tele2 and TalkPool entered into a partnership with the goal of building an IoT network based on LoRaWAN Technology in Gothenburg. This will enable many exciting customer projects in the Gothenburg region. "We are very happy and proud for the opportunity to help TalkPool with the development of the IoT solutions of tomorrow. For 30 years, Sigma has built a strong competence in software development and in recent years we have focused a lot on strengthening our expertise within IoT. Therefore, we look forward to cooperating with TalkPool and follow them in their ambitious goal to create innovative IoT services." said Robert Åberg, Head of IoT Solutions at Sigma Technology. For further information, please contact:Robert Spertina, Head of IoTTel: +46 70 797 6788robert.spertina@talkpool.com Erik Strömstedt, CEO Talkpool AGTel: +41 81 250 2020erik.stromstedt@talkpool.com    About TalkpoolTalkPool builds, maintains and improves telecommunication networks globally. Through its cutting-edge technical expertise, long experience and agile business model, TalkPool offers global telecom vendors and operators high-quality services on short notice no matter the location. Moreover, TalkPool is one of few companies with actual solutions and contracts in place in the exciting IoT-market. Remium Nordic AB is TalkPool’s Certified Advisor.   About Sigma Technology Group and SigmaSigma Technology Group is a global provider of product information, embedded & software design and offshore development. We are experts with a passion for technology and information and we take pride in always improving our deliveries. Our delivery philosophy is "Local Drive - Global Strength", which is why we have offices in many places around the world to be close to our customers. Sigma is owned by Danir AB and has about 3000 employees in eleven countries. For more information, visit www.sigmatechnology.se.

Final price in Edgeware’s IPO set at SEK 29 per share – trading on Nasdaq Stockholm commences today

· The final offering price has been set at SEK 29 per share, corresponding to a market value of all outstanding shares in Edgeware of approximately SEK 871 million. · The Offering comprised of 8,342,167 existing shares that have been offered by selling shareholders[1] (http://file///C:/Users/maria/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.Outlook/EEFEG481/Edgeware%20first%20day%20of%20trading%20press%20release%20(English).final.docx#_ftn1) and 5,172,413 newly issued shares that have been offered by the Company. In total, the Offering thus comprised 13,514,580 shares, corresponding to 45.0 per cent of the total number of shares outstanding in Edgeware, before any exercise of the over-allotment option. · The Company will receive gross proceeds of approximately SEK 150 million through the issue of new shares as part of the Offering. · In order to cover any over-allotment in relation to the Offering, Amadeus Capital Partners and Creandum have, on request from Joint Bookrunners, undertaken to offer up to 2,027,185 additional shares (the “Over-Allotment Option”), corresponding to up to 15.0 per cent of the number of shares in the Offering or 6.7 per cent of the total number of shares in the Company. · Assuming the Over-Allotment Option is exercised in full, the Offering will comprise 15,541,765 shares, which corresponds to a total value of approximately SEK 451 million (corresponding to approximately 51.7 per cent of the total number of shares in the Company). · Approximately 6,000 investors have been allotted shares in Edgeware and half of the total number of investors who applied for acquisition of shares within the Offering to the general public in Sweden have been allocated shares due to the large interest. Allocation to the general public in Sweden has been completed by drawing of lots. · Catella Fondförvaltning AB, Grenspecialisten Förvaltning AB, LMK Forward AB, Swedbank Robur Fonder AB and OstVast Capital Management Ltd (together the “Cornerstone Investors”) have in total acquired shares in the Offering corresponding to 45.6 per cent of the total number of shares in the Offering assuming the Over-Allotment Option is fully exercised, corresponding to approximately SEK 206 million. Their shareholdings will amount to 4.6 per cent, 5.7 per cent, 3.4 per cent, 6.4 per cent, and 3.4 per cent of the total number of shares in the Company following the Offering. · Settlement will take place on December 13, 2016. · Trading in the Company’s share on Nasdaq Stockholm commences today, December 9, 2016, under the trading symbol “EDGE”. Joachim Roos, CEO of Edgeware, comments: “We are proud of the strong interest we have received from investors from both Sweden and other countries in Europe. Our excitement about Edgeware’s potential is obviously shared and we look forward to serving our new investors as a listed company. Our focus now is on accelerating our sales activity to enable more customers to deliver amazing TV”. Mike Ruffolo, Chairman of the Board of Edgeware comments: “This is truly a great milestone for the company. The strong demand we have seen for the shares is evidence of the Company’s quality and global potential. We are grateful to our venture capital backers, Amadeus Capital Partners and Creandum, for their support in bringing us to this stage and, on behalf of the Board and the main shareholders, I look forward to continuing to support Edgeware as a listed company”. Edgeware in brief Edgeware was founded in 2004 and has since evolved into a global, high-tech company that develops and offers hardware and software systems as well as associated services that enable effective and scalable TV and video streaming over IP. The Company’s solutions are primarily sold to telecom and cable operators as well as to broadcasters and content owners that want to efficiently, securely and cost-efficiently make TV and video content available to their viewers. Edgeware’s solution is based on creating a decentralized content delivery network (CDN), where the Company’s hardware and software ensure that customers’ viewers can stream content from servers at the edge of a network, located closest to the viewer. This intelligently designed decentralised system ensures a high level of quality and delivery reliability and reduces the traffic load in the backhaul network (the network between the customers’ central data centre and the final part of the network, closest to the viewer). Between 2007 and 2015, the Company’s net sales grew by an average annual rate of 41 per cent per year and Edgeware’s net sales for the 12-month period ending 30 September 2016 amounted to SEK 232 million and the gross margin to 69 per cent. Advisors Carnegie Investment Bank is acting as Global Coordinator and Joint Bookrunner and Handelsbanken Capital Markets is acting as Joint Bookrunner in the Offering. Advokatfirman Vinge is legal advisor to Edgeware. Baker & McKenzie Advokatbyrå KB is legal adviser to the Global Coordinator and Joint Bookrunners. For further information, please contact: Gunilla Wikman, IR Manager, +4670-763 81 25, gunilla.wikman@edgeware.tv Important information This announcement is not and does not form a part of any offer for sale of securities. Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Japan or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States. The offering of securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. In any EEA Member State other than Sweden that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe,” “expect,” “anticipate,” “intends,” “estimate,” “will,” “may,” "continue," “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. In connection with the offer or sale of securities referred to herein, the Joint Bookrunners may over-allot securities/conduct stabilization or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. Any stabilization action or over-allotment will be conducted by the Joint Bookrunners in accordance with all applicable laws and rules. ---------------------------------------------------------------------- [1] (http://file///C:/Users/maria/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.Outlook/EEFEG481/Edgeware%20first%20day%20of%20trading%20press%20release%20(English).final.docx#_ftnref1)Amadeus Capital Partners, Creandum, Micron Technology and the Company’s founders (Joachim Roos, Lukas Holm and Kalle Henriksson)

Electrolux expectations for 2017

Market demand has been positive in Europe in 2016, although there have recently been signs of softer demand in some markets, including the UK. Demand for appliances in Europe is expected to grow by about 1% in 2017. Appliance demand in North America has grown for almost four consecutive years. We expect continued stable development and forecast volume growth of 2-3% in 2017. Continued pressures on household disposable income in Brazil and Argentina are forecast to have a negative impact on market volumes in these countries, which account for the majority of Electrolux sales in Latin America. Market demand in Argentina and Brazil together, is expected to decrease by approximately 5% in 2017. The work to increase operational efficiency continues and the net cost efficiency is planned to contribute positively with approximately SEK 1.6 bn for the year, excluding the impacts of raw materials and currency fluctuations. The Group’s capital expenditure level is expected to amount to approximately SEK 4 bn. Commodity prices in general have been trending upwards during 2016. Electrolux costs for raw materials are expected to increase by approximately SEK 900m in 2017 based on current market projections. Currency movements have been volatile throughout 2016. Recently, there have been reinforced fluctuations in several of Electrolux major currencies, most notably the Egyptian Pound which was floated in early November 2016. For 2017, at current exchange rates, a negative transaction impact for the Group of SEK 250m is expected. However, Electrolux expects a positive translation impact of SEK 250m. Electrolux is focused on achieving sustainable profitability in all business areas, with high priority on securing a Group EBIT margin of 6% over the business cycle. This will be achieved through innovative product launches and an active product portfolio management, in combination with product and structural cost efficiencies. In all, this will create additional value for our customers, employees and shareholders.

Finnair Traffic Performance in November 2016

Finnair Plc         Stock Exchange Release         9 December 2016 at 09:00 am EET Number of passengers grew 2.2% year-on-year In November, Finnair's overall capacity measured in Available Seat Kilometres grew by 1.7 per cent, and traffic measured in Revenue Passenger Kilometres grew by 1.5 per cent year‐on‐year. The passenger load factor declined by 0.2 percentage points to 76.0 per cent. The capacity in Finnair’s largest traffic area, Asia, grew by 2.3 per cent in November, and traffic grew slightly more, by 3.9 per cent on the back of higher passenger load factor. The new Fukuoka and Guangzhou routes were retired in October for the winter season. Hence the November destination range was the same as in the comparison period, and the capacity growth was due to the additional capacity introduced by the A350s. The capacity in American traffic declined by 4.2 per cent year-on-year, and traffic measured in RPK decreased 10.3 per cent. The contraction in capacity was due to unforeseen aircraft overhaul, which forced the cancellation of four round trips on the New York route, which was being operated by temporarily leased aircraft and flight crew during the month. European traffic remained largely unchanged as capacity grew by 1.4 per cent and RPK declined by 0.3 per cent year-on-year. The domestic capacity increased by 6.2 per cent, and traffic increased by 6.6 per cent year‐on‐year reflecting mostly increased flying to Northern Finland. In November, the cargo capacity in scheduled traffic measured in Available Tonne Kilometres grew by 2.2 per cent, and Revenue Tonne Kilometres increased by 5.8 per cent year-on-year. In addition, Finnair’s total freight capacity included three weekly freighter flights between Helsinki and Brussels, operated by DHL. In November, 75.9 per cent of all Finnair flights arrived on schedule (92.1). Traffic statistics for December 2016 will be published on Tuesday, 10 January 2017. Finnair Traffic Performance November 2016 November 2016  %-Change Year-to   date 2016 %-Change Total TrafficPassengers   1000 825,4 2,2 10 025,1 5,5Available   seat 2 570,2 1,7 31 188,7 6,7kilometres millRevenue passenger   1 953,6 1,5 24 915,0 5,6kilometres millPassenger   load 76,0 -0,2 p 79,9 -0,8 pfactor %Cargo   tonnes total 12 497,5 2,8 135 671,5 12,9Available   tonne 385,4 5,3 4 613,3 8,4kilometres millRevenue   tonne 249,5 2,2 3 049,1 7,6-kilometres millOverall   load 64,7 -2,0 p 66,1 -0,5 pfactor % EuropePassengers   1000 481,4 1,6 6 210,4 4,4Available   seat 998,8 1,4 12 270,9 2,6kilometres millRevenue   passenger 737,5 -0,3 9 663,9 2,8kilometres millPassenger   load 73,8 -1,2 p 78,8 0,1 pfactor % North AtlanticPassengers   1000 16,1 -13,5 272,1 11,4Available   seat 164,7 -4,2 2 460,5 22,3kilometres millRevenue   passenger 118,4 -10,3 1 958,7 16,0kilometres millPassenger   load 71,9 -4,9 p 79,6 -4,3 pfactor % AsiaPassengers   1000 133,0 3,8 1 636,7 5,6Available   seat 1 260,1 2,3 15 072,3 7,9kilometres millRevenue   passenger 1 001,0 3,9 12 340,0 6,1kilometres millPassenger   load 79,4 1,2 p 81,9 -1,4 pfactor % DomesticPassengers   1000 194,9 4,3 1 905,9 8,2Available   seat 146,6 6,2 1 385,0 6,6kilometres millRevenue   passenger 96,6 6,6 952,4 8,5kilometres millPassenger   load 65,9 0,2 p 68,8 1,2 pfactor % Cargo TrafficCargo   scheduled 10 993,0 5,3 119 764,7 14,2traffic total tonnesEurope   tonnes 2 342,3 6,2 24 079,6 20,2North   Atlantic 507,5 -30,0 8 309,2 12,3tonnesAsia   tonnes 7 979,3 8,4 85 771,5 13,1Domestic   tonnes 163,9 9,6 1 604,5 1,6Cargo   flights, 1 504,5 -12,6 15 906,8 3,6tonnes**Cargo   tonnes total 12 497,5 2,8 135 671,5 12,9Available   tonne 112,2 2,5 1346,0 5,8kilometres* millRevenue   tonne 74,8 3,9 820,3 13,3kilometres millAvailable   104,1 2,2 1258,5 5,9sched.cargo tonnekms*, mill.Revenue   67,3 5,8 738,5 14,0sched.cargo tonnekms, mill.Cargo load   factor* 66,6 0,9 p 60,9 4,0 p%-   North-Atlantic 34,8 -4,5 p 40,1 0,6 pcargo load factor* %- Asia   cargo load 71,0 0,8 p 64,0 5,0 pfactor* %Scheduled traffic 64,7 2,2 p 58,7 4,2 pCargo load factor*, * Operational calculatory capacity ** Including purchased traffic – Change %: Change compared to the figures of the respective periods in the previous year (p = percentage points) – Available seat kilometres, ASK: Total number of seats available, multiplied by the number of kilometres flown – Revenue passenger kilometres, RPK: Number of revenue passengers carried, multiplied by kilometres flown – Passenger load factor: Share of revenue passenger kilometres of available seat kilometres – Available tonne kilometres, ATK: Number of tonnes of capacity for carriage of passengers, cargo and mail, multiplied by kilometres flown – Revenue tonne kilometres, RTK: Total revenue load consisting of passengers, cargo and mail, multiplied by kilometres flown – Overall load factor: Share of revenue tonne kilometres of available tonne kilometres

Farstad Shipping ASA – Charter Agreements

Farstad Shipping ASA has been awarded the following charter contracts in Australia: ConocoPhillips Australia Exploration has issued a LOI to the AHTS Far Sirius (2014, UT 731 CD, 24,371 BHP) and the AHTS Far Saracen (2010, UT 731 CD, 23,664 BHP) to support their upcoming Barossa drilling campaign. This campaign is due to commence in January 2017. The INPEX- led Ichthys LNG Project has extended the AHTS Far Sword (2006, UT 712L, 16,000 BHP) contract with additional 17 months starting from 31 March 2018. McDermott’s Australia has awarded the PSV Far Seeker (2008, UT 751 E, 9,466 BHP) a contract for a period of 40 days firm plus 40 days options. The contract is due to commence within December 2016. McDermott’s Australia has also awarded two AHTS vessels contracts to assist with the mooring operations of the INPEX-led Ichthys LNG Project’s Central Processing Facility and FPSO. This is due to commence within Q2 2017. The commercial terms of the agreements will be kept private and confidential between the parties. - This is a clear demonstration of the ongoing standing of Farstad Shipping within Australia as the market leader and provides the Australian operations with a strong foundation heading into 2017, says Karl-Johan Bakken, CEO of Farstad Shipping ASA. Contacts: CEO Karl-Johan Bakken –  tel. +47 901 05 697 CFO Olav Haugland – tel. +47 915 41 809 Farstad Shipping’s fleet currently consists of 55 vessels (27 AHTS, 22 PSV and 6 SUBSEA) and 1 SUBSEA vessel under construction. The company’s operations are managed from Aalesund, Melbourne, Perth, Singapore, Macaé and Rio de Janeiro with a total of 1,725 employees engaged onshore and offshore. The company’s strategy is to be a leading quality provider of large, modern offshore service vessels to the oil industry. www.farstad.com 

EQT VI acquires Independent Vetcare from Summit Partners

· EQT VI has signed an agreement to acquire Independent Vetcare Limited (IVC), the third largest vet services provider in the UK, from Summit Partners · EQT VI will support IVC through both organic and acquisitive growth opportunities under the leadership of CEO David Hillier Run by and for vets, IVC was founded in 2011 through the merger of three veterinary groups, and has since grown rapidly through organic growth as well as a large number of add-on acquisitions. Today, IVC is the largest privately owned vet services platform in the UK with more than 290 sites and an online pet pharmacy. The company is primarily focused on first opinion care, complemented by referral hospitals, and operates a decentralized model promoting clinical freedom balanced with integrated support functions such as procurement, veterinary advisors and clinical boards. With its vet-friendly culture and reputation for clinical excellence, IVC has quickly grown into an organization of approximately 2,700 people, including 800 veterinarians. David Hillier, CEO of IVC says: “I am very proud of what we have achieved so far in IVC and we are all excited by what the future now holds. IVC has benefitted greatly from Summit´s deep experience in healthcare services and in scaling dynamic organizations like ours. EQT will enable us to continue to develop the group, to increase investment in our people and facilities and empower us to build the premium veterinary group in Europe. We will continue to focus on the values which are dear to us: Teamwork, transparency, client satisfaction and clinical excellence. In EQT we have a partner who shares these values and brings a wealth of experience in veterinary care and associated fields. We are excited to partner with EQT for the journey ahead.” Thomas Tarnowski, a Principal based in Summit Partners’ London office, who has served on the IVC Board of Directors since the firm’s investment in 2014, comments: “It has been an honour to work alongside David Hillier and the entire IVC team as they carried out their vision of creating a vet-friendly culture that enables practice owners to maintain clinical autonomy, while gaining the benefits of joining a larger organization. We are delighted to transition IVC to EQT for the next phase of the company´s growth.” Per Franzén, Partner at EQT Partners, Investment Advisor to EQT VI, says: “We are very impressed by IVC and the leading position that management has built in the UK market thanks to its passion for veterinary care. EQT’s strong expertise and deep vet services sector experience from Evidensia, alongside EQT’s industrial network, will support IVC’s further growth and development of a veterinary group which keeps decision-making in the hands of the clinician.” The transaction is expected to close in early 2017. The parties have agreed not to disclose the transaction value. Contacts: Per Franzén, Partner at EQT Partners, Investment Advisor to EQT VI, +46 8 506 554 48 Kerstin Danasten, EQT Press Contact, +46 8 506 55 334 Susan Barr, Summit Partners, Vice President of Marketing, +617 824 1026 About EQT EQT is a leading alternative investments firm with approximately EUR 31 billion in raised capital. EQT Funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com (http://mandrillapp.com/track/click/30911255/www.eqtpartners.com?p=eyJzIjoiQ2U1cDJCN0sxc3pIS01COS1DMUtIMXhFWUFjIiwidiI6MSwicCI6IntcInVcIjozMDkxMTI1NSxcInZcIjoxLFwidXJsXCI6XCJodHRwOlxcXC9cXFwvd3d3LmVxdHBhcnRuZXJzLmNvbVwiLFwiaWRcIjpcIjBhNjY1ZGEzMjg4YzQ5MTVhZTY4MTZiMWIzOWJjNTUzXCIsXCJ1cmxfaWRzXCI6W1wiNjNkNWM4MjU1NmYzMWZjZjJjMGRiMTY1OTkwMzNkODA5NzI3M2U0NVwiXX0ifQ) About IVC IVC is the largest privately owned vet services platform in the UK with more than 290 sites and an online pet pharmacy. IVC employs approximately 2,700 FTEs, including 800+ FTE veterinarians. More info: www.independentvetcare.co.uk About Summit Partners Summit Partners is a global growth equity firm that is currently investing more than USD 7.2 billion into equity and fixed income opportunities. Summit has invested in more than 440 companies in healthcare, life sciences, technology and other growth sectors. These companies have completed more than 140 public offerings, and more than 165 have been acquired through strategic mergers and sales. Summit maintains offices in North America and Europe, and invests in companies around the world. More info: www.summitpartners.com In the United States of America, Summit Partners operates as an SEC-registered investment advisor. In the United Kingdom, this document is issued by Summit Partners LLP, a firm authorized and regulated by the Financial Conduct Authority. Summit Partners LLP is a limited liability partnership registered in England and Wales with registered number OC388179 and its registered office is at 20–22 Bedford Row, London, WC1R 4JS, UK. This document is intended solely to provide information regarding Summit Partners’ potential financing capabilities for prospective portfolio companies.